Application for DFC-DPA Loan Program

(DFC-014)

OMB No. 

Responses to questions which call for estimates or projections should take the form of 

good faith statements made to the best of the applicant’s knowledge and belief. 

Statements of fact provided in this document must be accurate as of the date of 

submission. Anyone who knowingly makes a false statement with the intent to influence 

DFC’s loans or other investments may be criminally prosecuted. Such false statements 

are also grounds for DFC to terminate a commitment or declare a contract default. These 

rights are in addition to any other rights or remedies available to the United States 

government. Neither submission nor acceptance of this application implies that the 

proposed transaction is eligible for support or that support will be provided.

Information provided in this form will be deemed designated as “confidential commercial 

information” in accordance with Freedom of Information Act (FOIA) regulations at 22 

C.F.R. Part 706, and will be treated as such to the extent permitted by applicable law.

Paperwork Reduction Act Notice: This information is required to obtain or retain benefits. 

Federal agencies may not collect information unless a valid OMB Control Number with an 

expiration date that has not expired is displayed. The public reporting burden for this 

collection of information is estimated to average 90 minutes per response, including the 

time for reviewing instructions, searching existing data sources, gathering and 

maintaining the data needed, and completing and reviewing the collection of information. 

Send comments regarding this burden estimate or any other aspects of this collection of 

information, including suggestions for reducing this burden, to Agency Clearance Officer, 

Records Management, United States International Development Corporation, 1100 New 

York Ave., NW, Washington, DC, 20527 and to the DFC Desk Officer at the Office of 

Information and Regulatory Affairs, Office of Management and Budget, New Executive 

Office Building, Room 10202, Washington, DC 20503.

A0001
This Form and any attached supporting documentation will enable DFC personnel to make a 

preliminary determination of whether your proposal meets eligibility and basic underwriting 

requirements. DFC-DPA Loans are limited to projects that support the national response 

and recovery to the COVID-19 outbreak, or the resiliency of any relevant domestic supply 

chain. Please click here to review the basic eligibility requirements and the DFC-DPA Loan 

Program origination process. For general questions or eligibility questions, please email [email 

address of new DFC domain to be added]. If a particular question on this form is unclear, please 

email [email address of new DFC forms domain to be added].

If you are applying for a Funds transaction, please skip to Section 2.

Section 1: Project-Specific Transactions

QUESTION 1: SPECIFY FINANCING STRUCTURE

The DFC-DPA Loan Program (DDLP) supports a wide variety of transactions by providing direct 

financing. Though each transaction may have unique structural aspects, all transactions fit into 

one of two basic structural categories. Please read the definitions below and choose the structure 

that best fits the type of support that you are seeking. 

Project Finance/Investment: DFC provides financing to a stand-alone project or single 

purpose entity. 

Corporate Finance/Investment: DFC provides financing to a general corporate entity that 

already has an operational track record. 

QUESTION 2: IDENTIFY THE PROPOSED BORROWER/INVESTEE

In each DFC-supported transaction, DFC enters into a contractual relationship with a 

Borrower/Investee (in the case of Project Finance or Corporate Finance transactions). Please list 

the location and contact information for that party. If that party has not yet been 

formed/incorporated, please list approximate information that will allow us to create a placeholder 

for that party in our transaction tracking systems.

Borrower/Investee

 Name:

 Address (incl. city and country):

 website (if avail): 

DUNS Number:

U.S. Tax Identification Number: or N/A – Not a US Taxpayer 
QUESTION 3: IDENTIFY THE APPLICANT REPRESENTATIVE

Please provide contact information for the individual who will be DFC’s primary point of contact 

regarding this application. 

 Name and Title of Representative:

Relationship to the Borrower/Investee/Guaranteed Party: 

 Name of Representative’s Company (if different from the Borrower/Investee/Guaranteed Party)

 Address:

 Phone Number 1 (office):

 Phone Number 2 (mobile)

E-mail

QUESTION 4: IDENTIFY THE KEY PARTIES INVOLVED WITH THE TRANSACTION 

Evaluating the business entities and/or individuals that will own, manage or make other critical 

contributions to the transaction being financed is an important part of DFC’s underwriting process.

Please attach detailed chart(s)/schematic(s) showing the structure of the proposed transaction 

and key relationships. These may include ownership charts, organizational/management 

structures, contractual relationship schematics, etc. 

Please list and provide requested information on each of the following types of entities/individuals. 

If an entity/individual plays multiple roles in a transaction, only list them once and indicate their 

most important/primary role: 

• Each business entity/individual that owns 10% or more (either directly or indirectly) of the

Borrower/Investee/transaction.

• Each business entity/individual that does or intends to provide credit support (e.g. a

guarantor)

• Each business entity/individual that does or will have a significant managerial relationship

with the Borrower/Investee/transaction (e.g. executives/directors).

• Each business entity/individual that does or will have a primary contractual relationship

with the Borrower/Investee (e.g. construction contractor, operations and maintenance

contractor, hotel management company, etc.)

Name

Type of Entity

Country of Citizenship (for 

Individuals) or Incorporation (for 

Business Entities)

Primary Relationship to 

Borrower/Investee/Transaction

Veteran Owned or Led?

Minority Owned or Led?

Women Owned or Led?

If yes, please provide:

(b) (6)

(b) (6)
% owned by women

# of women on Board of Directors

names and titles of women owners 

and executives:

QUESTION 5: DESCRIBE THE TRANSACTION

Please provide a brief description of the proposed transaction, making sure to address the 

following:

• What are the objectives of the proposed transaction?

• What factors or resources under the control of the involved parties will contribute most toward

meeting those objectives and why?

• How would DFC’s participation in the transaction contribute to its success?

Please attach the following supporting documents:

Business Plan/Preliminary

Information Memorandum 

Financial Projections Model 

Historical Financial Statements 

QUESTION 6: DETAIL COSTS AND FUNDING

[If the Financing Structure chosen in Question 1 was Project Finance/Investment, then the online 

form will show the following:]

For a Project Finance transaction, please provide a detailed list of the estimated project costs and 

the types and amounts of funding that will be used to cover them. Remember to include both 

hard/physical asset costs (e.g. buildings or equipment) and soft/implementation costs (e.g. legal 

or consultant services, fees, contingency etc.) in the cost estimate. The total cost amount in 

Column A must equal the total funding amount in Column B. For an example, please click [here].

Column A Column B

Cost Item USD % Funding Source USD %

Debt:

DFC loan (indicate proposed term)

Other term debt (indicate proposed term)

Supplier financing

Subordinated Debt: 

Third party subordinated debt 

Shareholder subordinated loans

Equity: 

Cash

(b) (4)

(b) (4)
In-kind contribution1

Grants

Other (please describe)

Total Project Costs: Total Project Funding

[If the Financing Structure chosen in Question 1 was Corporate Finance, then the online form will 

show the following:]

For a Corporate Finance transaction, please provide a detailed list of how the DFC-supported 

funding would be used and how the proposed transaction would affect the existing corporate 

funding structure/leverage of the Borrower. For an example, please click [here].

Uses of the DFC-supported Funding

Cost Item USD %

Total Costs

Balance Sheet Comparison

Existing Balance 

Sheet

USD % Proposed Future Balance 

Sheet

USD %

Total Assets Total Assets

DFC Debt

Total Debt/Liabilities Non-DFC Debt/Liabilities

Net Worth

Non-DFC Net Worth

Would DFC debt be used to repay any existing debt? 

If yes, please describe the source and current terms of the debt that would be repaid and why the 

repayment is important to the overall objective of the transaction. 

1 An in-kind contribution could be a hard asset such as a building, land or equipment. In order for DFC to credit it as 

an equity contribution, it must be titled to the Borrower, and DFC must receive reasonable documentation of its 

market value (e.g. a recent appraisal, sales invoice, etc.)
QUESTION 7: DESCRIBE COLLATERAL AND/OR CREDIT ENHANCEMENTS (IF 

APPLICABLE)

) 

QUESTION 8: MANAGEMENT EXPERIENCE AND TRACK RECORD 

Briefly describe relevant experience (in the sector, in the market, etc.) that the key parties 

(individually or as a team) may contribute towards the success of the proposed transaction. 

Please attach a document compiling CVs or other documentation that demonstrates 

this experience:

) 

Guaranties from creditworthy individuals or companies (Specify name(s) of guarantor(s):)

Irrevocable standby letter(s) of credit 

Debt Service Reserve Account 

“Key Man” Life Insurance

Other (describe:

) 

Liens/Mortgages on other assets (Specify types/locations: 

DFC usually requires a collateral/credit enhancement package tailored to the specific risks of a 

given transaction. Following are indicative categories of collateral/credit enhancement that DFC 

may require. Please indicate below those categories that may be available (check all that apply): 

Pledge of shares of the Borrower 

Liens/Mortgages on Borrower assets (Specify types/locations: ___________

____________________________

_____________
Question 9: PROVIDE INFORMATION ON PRIVATE SECTOR SOURCES OF FINANCING

DFC does not compete with private sector providers of financing. Therefore, DFC requires that 

applicants: (a) evaluate the possibility of obtaining financing from private sources and (b) decide 

to pursue DDLP financing because private financing is not available on reasonable terms sufficient 

to make the investment viable.

Have you evaluated the possibility of obtaining financing for this transaction from private sector 

sources?

Yes No

Have you determined that private sector financing is not a viable option in this case? Yes No

If Yes, please list the private sector funding source(s) you have approached regarding this 

transaction and explain why private financing is not a viable option (i.e., unworkable tenor 

and/or pricing).
SUBMISSION/SIGNATURE Page

I certify that:

the Applicant or any owner of the applicant is not presently suspended, debarred, proposed 

for debarment, declared ineligible, voluntarily excluded from participation in this transaction 

by any Federal department or agency, or presently involved in any bankruptcy. 

the Applicant, any owner of the applicant, or any business owned or controlled by any of 

them, has not ever obtained a direct or guaranteed loan from any Federal agency that is 

currently delinquent or has defaulted in the last 7 years and caused a loss to the 

government. 

the Applicant (if an individual) or any individual owning 20% or more of the equity of the 

Applicant is not subject to an indictment, criminal information, arraignment, or other means 

by which formal criminal charges are brought in any question, or presently incarcerated, or 

on probation or parole. 

Within the last five years, for any felony, the Applicant (if an individual) or any individual 

owning 20% or more of the equity of the Applicant has not: (1) been convicted; (2) pleaded 

guilty; (3) pleaded nolo contendere; (4) been placed on pretrial diversion; or (5) been placed 

on any form of parole or probation (including probation before judgment). 

all loans will be used for eligible projects within the United States. 

I certify that the statements and information provided herein are true to and correct to the 

best of my knowledge and belief. I understand that knowingly making a false statement to 

obtain this loan is punishable under the law, including under 18 U.S.C. 1001 and 

3571 by imprisonment of not more than five years and/or a fine of up to $250,000 or twice 

the gross pecuniary gain from the offense or twice the gross pecuniary loss to another 

person; and, if submitted to a federally insured institution, under 18 U.S.C. 1014 by 

imprisonment of not more than 30 years and/or a fine of not more than $1,000,000.”

Name:

Title/Role in Transaction:

Email Address:

(b) (6)
Note: Some of the questions in the form require the attachment of specific documents. In 

addition, at the bottom of every page of the electronic form, there is a link that will allow the 

applicant to attach additional supporting documentation as necessary. A list of the essential 

supporting documentation requested by DFC is as follows:

SUPPORTING DOCUMENTATION

1. COMPLETE BUSINESS PLAN/PRELIMINARY INFORMATION MEMORANDUM

Since DFC supports a variety of transaction structures in many different sectors/industries, it is 

not possible to provide a standard business plan template. The following checklist details the 

items that applicants should consider as they prepare their business plans. Please provide as 

complete a business plan as possible.

Investment/Transaction Summary

• Investment/Transaction Description/Status Describe the purpose for which the DDLP is to

be used and investment made to date, market or feasibility studies performed, status of

documentation/permits/government consents, environmental studies, past and ongoing

consultations with project-affected communities (including disadvantaged and vulnerable

groups), etc.

• Financial Plan and Credit Support Describe the proposed DFC and other lender debt --

loan amount, tenor, grace period -- and source, timing and amount of equity contributions,

grants or other funding; describe any proposed collateral and other credit support

Key Parties

• Owners/Shareholders, Guarantors, Management, Contractors, Regulators -- Provide

detailed information on the key parties associated with the transaction, fully explain their

role(s), and explain the relationships among them. If certain characteristics (e.g. a strong

credit rating) or capabilities/experience (e.g. a strong track record in a given market or

industry) are important to that party being considered a good candidate to fulfill their role in

the transaction, please highlight that information.

Sector/Target Market/Economics

• Sector/Industry Describe the competitive environment in which the investment is being

made and any recent or emerging trends that may affect its success.

• Product/Services Describe the ultimate products or services that this investment will

produce, and in what quantity.

• Economic/Technical Specifications If relevant, provide economic assumptions, technical

parameters, construction plans/schedule, equipment/land to be procured, off-take

arrangements, etc.

• Agreements List any key contractual arrangements necessary to the success of the

investment such as concession or franchise/royalty agreement(s), construction contract(s),

offtake agreement(s), environmental impact studies, feasibility studies, marketing studies,

technical assistance agreement(s), management services agreement(s), lease(s), etc. (and

attach electronically if available)

Legal, Economic, Political Environment and Government Participation

• Licenses/Permits List all licenses, permits, consents, approvals, environmental

requirements etc. required by the country/local government and the status of such

documentation.
• Legal Regime List local laws, regulations or pending reforms that will impact the investment

or the sector.

• Government/Multilateral Participation Describe any government or multilateral involvement

in the investment or the sector and any government incentives such as tax holidays.

• Litigation or Dispute Resolution Describe any litigation or community dispute or complaint

resolution processes that have occurred or are occurring involving any of the key parties that

could affect this investment.

Transaction Strengths/Risks and Risk Mitigation

• Strengths Describe those factors that contribute to the long-term viability of the

investment/transaction.

• Risks Describe risks such as credit risks, sector/market risks and competition, operational

and management risks, economic risks, legal/regulatory risks and environmental, and what

steps the Borrower/Investee/Guaranteed Party will take to mitigate such risks and provide

access to accountability and remedy for negative project impacts on individuals and

communities.

2. Financial Projections Model

The financial projections model should cover at least the entire proposed term of the DDLP

financing. It should include detailed, financially-justifiable assumptions on all key drivers of the 

proposed transaction and should clearly demonstrate how funds provided under the DDLP will 

be repaid or recouped successfully. The model should also include financial statements (i.e.,

balance sheet, income statement, cash flow statement) and ratios or other financial 

measurements relevant to the industry/transaction type being modeled. In addition, the model 

should be structured in such a way as to make it simple to adjust key assumptions and thereby 

analyze potential financial performance under adverse conditions.

If the applicant does not already have a financial projections model that meets these criteria, 

DFC has provided a template (link to model template and user guides) that may assist some 

applicants in creating a model. Please note that this template is not designed to model financial 

institutions or other entities with lending or leasing portfolios. 

3. Historical Financial Statements

Evaluating the financial strength of parties upon which the transaction will depend (primary 

investors, guarantors, key contractors or off-takers) is an important part of DFC’s evaluation. For 

each such party, please provide financial statements, preferably prepared in accordance with U.S. 

Generally Accepted Accounting Principles (“U.S. GAAP”) or International Financial Reporting 

Standards (“IFRS”). Financial Statements must be prepared in English or accompanied by a 

certified English translation. Listed below are the types of financial statements that should be 

submitted for each type of entity:

For a public corporation: - 10K or equivalent (most recent 3 years)

- 10Q or equivalent (most recent quarter)

For a private corporation: - Annual Financial Statement (preferably audited; most recent 3

years)

- Quarterly Financial Statement (most recent quarter)

- Tax Return (most recent 3 years)
For a partnership: - Annual Financial Statement (preferably audited; most recent 3 

years)

 - General Partner information, including (i) current signed Statement 

of Net Worth (assets, liabilities, net worth) and (ii) ownership

For an individual: - Current Signed Personal Financial Statement (assets, liabilities, net 

worth) – provide link to DFC-005 (fillable PDF)

 - Tax Return (most recent 3 years)
Section 2: Investment Funds Transactions

Proposal Date 

GP Main Point of Contact (First Name)

GP Main Point of Contact (Last Name)

GP Main Point of Contact (Email)

GP Main Point of Contact (Phone Number)

Name of Firm

Address of Firm Headquarters

City of Firm Headquarters

Country of Firm Headquarters

Other Firm Locations (cities)

Year Firm Established

Website of Firm
FUND OVERVIEW

Fund Name

Fund Target Size in USD (including DFC amount)

Max Fund Target Size in USD (including DFC amount)

Min Fund Target Size in USD (including DFC amount)

Proposed GP Commitment (%)

Proposed DFC Commitment

Fund Sectors 

If Other Sectors/Industries (please describe)

Projected Fund Multiple and IRR returns (gross)

Brief Description of the Fund and its Strategy 

Brief Description of the Fund for Public Disclosure After 

Approval (character range 40-149) 
MANAGEMENT OVERVIEW

Fund Team Formation: Describe how the Fund 

Manager and the team were initially formed and 

provide a brief history of how they have evolved to 

date. You may also refer to appropriate sections in 

the PPM or marketing presentation.

Number of Partners

Total Number of Employees/Number of Senior 

Investment Professionals

Is the General Partner or Investment Manger a womenowned enterprise or women-led enterprise? 

Please provide the current or projected number of 

female members of the GP’s or FM’s board of directors 

or other governing body, if applicable

GP _________#

FM___________#

Firm’s Assets Under Management

Number of Funds Previously Managed by this Firm

SENIOR INVESTMENT TEAM BACKGROUND

Name Title Year 

joined firm

Location (city, 

country)

Focus (industry, 

function, if any)

Prior work experience 

(include firm, position 

number of years)

Education
LP BASE

Total Capital Raised to Date in USD

Total Capital Raised to Date (% of Target Fund Size)

First Close Date (actual/anticipated) and Amount

(i) Explain why you are seeking DDLP funding. (ii)

What efforts have been taken to raise capital from

private sector investors and what has been the

outcome of those efforts? (iii) Is there a lack of

available private sector support for the Fund, or for

portfolio companies and if so for what reason?

List of Investors in prior funds and those who have 

Committed to this Fund and Amount

Name Commitment to prior 

fund(s)

Commitment to this 

Fund

Location (country)

List of new Investors committed to this Fund Name Commitment Location (country)

TRACK RECORD

Attach a summary of prior fund performance (see 

Track Record template) 
INVESTMENT POLICY & ESG

Describe the impact you believe the Fund will have 

(e.g., job creation, development of critical supply 

chains, number/value of product produced or 

supplied ,).

Will the Fund target investments that are femaleowned or serve female clients, clients located in 

rural areas, or other underserved populations?

If so, what percentage will be dedicated to these 

populations?

Women:_______%

Rural:_______%

Other: _____%

Number and percentage of female staff (GP, Fund 

Manager and Fund) 

Number/Percentage of staff

General Partner

Fund Manager

Fund

Please describe the Fund’s practices concerning 

provision of accountability and access to remedy 

communities.

OTHER - MISCELLANEOUS

(i) Describe any potential conflicts of interest of

which you are aware. (ii) How do you plan to

resolve potential conflicts of interest within the

Fund, or with other investment vehicles managed

by your organization or its affiliates?

Are there any substantive litigation, dispute 

resolutions, or regulatory actions brought 

against the manager, its principals or any 

portfolio companies?

If yes, please attach an explanation describing any 

litigation, community dispute, or complaint 

resolution processes that have occurred or are 

occurring involving the manager, its principals 

and/or its portfolio companies.

 ATTACHMENTS

Attach the Fund's most recent 

marketing presentation

Attach the Fund's investment pipeline

Attach the Fund's PPM (if available)

Attach Fund’s ESG Policies

Attach Fund’s Know Your Customer Policies

Attach LPA (if available)

PROPOSAL DOCUMENTS

Document Name Description Document Date File Name
SUBMISSION/SIGNATURE Page

I certify that:

the Applicant or any owner of the applicant is not presently suspended, debarred, proposed 

for debarment, declared ineligible, voluntarily excluded from participation in this transaction 

by any Federal department or agency, or presently involved in any bankruptcy. 

the Applicant, any owner of the applicant, or any business owned or controlled by any of 

them, has not ever obtained a direct or guaranteed loan from any Federal agency that is 

currently delinquent or has defaulted in the last 7 years and caused a loss to the 

government. 

the Applicant (if an individual) or any individual owning 20% or more of the equity of the 

Applicant is not subject to an indictment, criminal information, arraignment, or other means 

by which formal criminal charges are brought in any question, or presently incarcerated, or 

on probation or parole. 

Within the last five years, for any felony, the Applicant (if an individual) or any individual 

owning 20% or more of the equity of the Applicant has not: (1) been convicted; (2) pleaded 

guilty; (3) pleaded nolo contendere; (4) been placed on pretrial diversion; or (5) been placed 

on any form of parole or probation (including probation before judgment). 

all loans will be used for eligible projects within the United States. 

I certify that the statements and information provided herein are true to and correct to the 

best of my knowledge and belief. I understand that knowingly making a false statement to 

obtain this loan is punishable under the law, including under 18 U.S.C. 1001 and 

3571 by imprisonment of not more than five years and/or a fine of up to $250,000 or twice 

the gross pecuniary gain from the offense or twice the gross pecuniary loss to another 

person; and, if submitted to a federally insured institution, under 18 U.S.C. 1014 by 

imprisonment of not more than 30 years and/or a fine of not more than $1,000,000.”

Name:

Title/Role in Transaction:

Email Address:
A0002
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & 

Active Pharmaceutical Ingredients for Essential Medicines

Eastman Kodak Company. Confidential Information Page 1 of 4

Volume II: Cost Proposal

Full Proposal Submitted for Consideration under 

Solicitation 

Research Area of Interest:

This proposal is made in agreement with all the terms and conditions of this Solicitation.

Establishing a U.S. Center of Excellence for the Production 

of Key Starting Materials & Active Pharmaceutical 

Ingredients for Essential Medicines

Prime Offeror: 

Eastman Kodak Company (Kodak)

Tel: 

e-mail:

Date of Submission: June 3, 2020

Updated: June 5, 2020

Proposed Period of Performance: 

06/2020 to 12/31/2026

DUNS Number: 002206183

CAGE Code: 19139 

TIM: 16-0417150

NAICS: 339900

Authorized Representative / Administrative Contact: 

Jim Continenza, Executive Chairman

Tel:

______________________________________

Technical Contact: Terry Taber, Chief Technology 

Officer and Senior VP, Advanced Materials & 

Chemicals

Tel: 

Proposed Cost: $

FOR DISCUSSION PURPOSES ONLY. The estimated costs contained in this proposal are 

preliminary. This description has been prepared by the management of Kodak and are based on 

Kodak’s current good faith views and assumptions believed to be reasonable as of this date. The 

estimated costs are subject to significant uncertainties and contingencies, many of which are 

beyond Kodak’s control, including local, regional and global economic conditions and 

fluctuations in the cost of building materials, labor and commodities. Actual costs may differ 

materially from these estimates. Kodak makes no express or implied representation or warranty 

as to the achievability of any cost estimates. Kodak expressly disclaims any and all liability that 

may be based on any inability to achieve any particular cost estimate.

A0003

(b) (4)

(b) (6) (b) (6) (b) (6) (b) (6)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & 

Active Pharmaceutical Ingredients for Essential Medicines

Eastman Kodak Company. Confidential Information Page 2 of 4

TABLE OF CONTENTS

1. Cost Summary......................................................................................................................... 3

2. Cost Proposal .......................................................................................................................... 4

2.1 General............................................................................................................................ 4

2.1.1 Cost Reasonableness................................................................................................. 4

2.1.2 Profit Including Percentages..................................................................................... 4
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active Pharmaceutical 

Ingredients for Essential Medicines

Eastman Kodak Company. Confidential Information Page 3 of 4

1. COST SUMMARY

Cost Proposal: Below is a brief cost summary. This proposal estimate is based upon a Cost-plus-fixed-fee (CPFF) model.

Cost/CLIN: Total cost for each CLIN. These options have been presented in this summary where appropriate.

Table 1. Summary Table of all Kodak Costs

SUMMARY by CLIN (in millions)

TOTAL

CLIN 1: Procurement and Storage of KSMs for Essential Medicines in Shortage

CLIN 2: Establish U.S.-Based Production of KSMs for Essential Medicines in Shortage

CLIN 3: Establish Strategic API Ingredient Reserve (SAPIR) Facility

CLIN 4: Establish U.S.-Based Advanced Manufacturing Capability for KSMs and APIs

CLIN 5: Establish a R&D Center of Excellence for Process and Analytical Test 

Development to Support Continuous Manufacturing and Testing of KSMs and 

APIs

CLIN 6: Establish a Diagnostic Reagent Manufacturing Facility

Total Direct Costs

G&A

Total Proposed Cost Excluding Fee

Proposed Fee/Profit

TBD 

(contracts)

(b) (4)

2025

WBS Task Budget123412341234123412341

1 Procurement and Storage of KSMs for Essential Medicines in Shortage

1.1 Procurement of KSMs

1.2 Storage of KSMs 2 Establish U.S.-Based Production of KSMs for Essential Medicines in Shortag

2.1 Development of KSM manufacturing processes

2.2 Manufacture of KSMs (304) 3 Establish Strategic API Ingredient Reserve (SAPIR) Facility

3.1 Construction of new storage facilities

3.2 Procurement of new equipment

3.3 Establish compliant materials handeling systems 4 Establish U.S-Based Advanced Manufacturing Capability for KSMs and APIs

4.1 Retrofit of Building 303 for cGMP Manufacturing

4.2 Construction of new cGMP Hybrid - CM Manufacturing 

4.3 Validation of new facility

4.4 Manufacture of API (Startup cost)

4.5 Construction of Starting Material Facility #1 (hydrogenation)

4.6 Construction of Starting Material Facility #2 (nitration)

47 Manufacture of KSMs from new facilities 5

Establish a Center of Excellence for Continuous Manufacturing and Testing

of KSMs and APIs

5.1 Renovation of existing manufacturing facilities

5.2 Purchase of essential equipment

5.3 Commissioning of CoE

5.5 Process Development- outsourced (15 Compounds)

5.4 Transfer of continuous KSM manufacturing processes

5.6 Process Development CoE 6 Establish a Diagnostic Reagent Manufacturing Facility

6.1 Renovation of existing manufacturing facilities

6.2 Procurement of new equipment

6.3 Establish compliant manufacturing and testing systems

6.4 Manufacture of diagnostic reagents

6.5 Storage of diagnostic reagents

Total

2020 2021 2022 2023 2024

A0004

(b) (4)

PROPERTY OVERVIEW

SITE CONTROL Eastman Business Park division of Eastman Kodak 

Company (primary owner and developer)

COMMON AREA MAINTENANCE Eastman Business Park

UTILITIES Provided by Recycled Energy Development (R.E.D)

TELECOMMUNICATIONS Several providers available onsite

NUMBER OF DEVELOPABLE ACRES 1,200 acres total (700 owned by Kodak, 500 by others)

300 acres ready for development in the whole site

NUMBER OF STATE OR 

FEDERAL WETLANDS

None

SHAPE AND CONFIGURATION 

OF PROPERTY

Flat, previously developed, various utilities present 

throughout 

IDEAL INDUSTRIAL APPLICATIONS Food processing, biomanufacturing, greenhouse 

agriculture, chemical processing, roll to roll coating, 

manufacturing, energy storage and photonics

Light manufacturing and industrial, distribution, office and 

laboratory space

RESEARCH AND DEVELOPMENT Multiple laboratory and office facilities, ideal for R&D 

applications

ZONING AND PERMISSABLE USES 16 million square feet of building space zoned for 

manufacturing, distribution, office and laboratories 

(10 million owned by Kodak)

Zoning permits required for new build

EXISTING PERMITS Permits for management of waste, storage of materials

AVAILABILITY Parcels available for lease, some for sale. Buildings 

available for lease or sale. Theater, dining and conference 

facilities available for rent. 

See www.eastmanbusinesspark.com/park-availability for 

listings
TRANSPORTATION ACCESS

INTERSTATE West end of the Park borders Route 390 with highway 

access to interstate system

East end of the Park borders Route 104 which intersects 

with interstate 590 - 5 minutes drive

RAILWAY 13 miles of track within the Park, some buildings have 

direct rail service

AIRPORT Rochester International Airport (ROC). 10 minutes drive 

from West end, 17 minutes from East end

CANAL 10 minutes to the Erie Canal for delivery of equipment too 

large for highways or rail service

PORT OF ROCHESTER 14 minutes to Port of Rochester (Lake Ontario)

PUBLIC TRANSPORTATION Rochester Transit System (RTS) service to Lake Avenue 

(Route 1) and West Ridge Road (Routes 14 and 106)
UTILITIES

ELECTRIC SERVICE 117 megawatts firm capacity with backup 

inter-connections with the public utility

STEAM 1,500,000 pounds per hours firm capacity from utility-grade 

boilers with emergency backup

WATER 54 million gallons per day nominal capacity. 

Backup from public water systems

WASTE WATER TREATMENT 

AND SEWER

36 million gallons per day capacity with Title V / RCRA 

permitted multiple hearth incinerator

CHILLED WATER 60,000 tons installed capacity – nominal supply 

temperature 40°F

HIGH-PURITY WATER 300 gal/min firm capacity of reverse osmosis deionized 

water - minimum resistivity 2 megohms

DEMINERALIZED WATER Treated process water using anion and cation exchangers 

with maximum conductivity of 4 micromhos

COMPRESSED AIR 47,000 standard cubic feet per minute installed capacity

NITROGEN 148,000 standard cubic feet per hour installed on-site 

plant capacity 

NON-HAZARDOUS WASTE 

DISPOSAL

General trash, metal, plastic and corrugated service by 

Waste Management

HAZARDOUS WASTE DISPOSAL Hazardous waste management supplied by Clean Harbors

NATURAL GAS Available through R.E.D. and local suppliers
AMENITIES

THEATER 1,968 seat theater, 180 seat studio theater

CONFERENCE CENTER Multiple conference rooms with capacity from 8 to 200, 

projectors and conference phones available

VISITOR CENTER

Exhibits celebrating Kodak’s past and present. Café and 

retail space. See the first digital camera invented by 

Kodak, one of Kodak’s Oscar statuettes and much more.

GALLERY 1,444 sq. ft. gallery space with two conference rooms.

FITNESS CENTER 9,000 sq. ft., cardio, strength training, lockers and showers 

DINING ROOM WITH KITCHEN Seats 350 people. 7,190 sq. ft.

CAFETERIAS Three full service cafeterias
ONSITE TECHNICAL SERVICES

ANALYTICAL SCIENCES Chemical and Materials Characterization, Manufacturing 

Problem Solving, Research and Development Innovation, 

Reverse Engineering / Product Deformulation, Routine 

Analytical Testing

SPECIALTY CHEMICALS Full service specialty and custom chemical manufacturer 

offering the flexibility of batch operations and expertise in 

process development, design for manufacturing and 

statistical process control

SOLVENT RECOVERY We recycle solvents. ISO 14001 certified. World-class 

Health, Safety and Environmental support staff. Highly 

trained engineers, operators, and mechanics.

ROLL-TO-ROLL COATING AND 

TESTING SERVICES

Take your materials from laboratory bench to roll-to-roll 

manufacturing at any scale. Range of coating and testing 

capabilities to create your products and evaluate how they 

will perform
SITE SERVICES

CONSTRUCTION AND PROJECT 

MANAGEMENT

Improve construction approaches, hit project schedules, 

enhance communication, achieve higher quality of work and, 

perhaps most importantly, reduce costs

ENVIRONMENTAL, HEALTH 

AND SAFETY

Deep knowledge of regulations, strong relationships with 

regulatory agencies 

COMMUNICATION SERVICES KODAK Communication Services has a full-service team of 

designers, multimedia developers, writers and localization 

specialists who create innovative marketing materials and 

technical publications to meet unique challenges, 

opportunities, and budgets.

SECURITY AND SITE ACCESS 24X7 operation

FIRE AND EMERGENCY SERVICES 24X7 operation (with backup support from municipalities


Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 2 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

2) Government Notice for Handling and Submitting Proposals

This proposal shall be used and disclosed for evaluation purposes only, and a copy of this 

Government notice shall be applied to any reproduction or abstract thereof. Any authorized 

restrictive notices, which the submitter places on this proposal shall be strictly complied with. 

Disclosure of this proposal outside the Government for evaluation purposes shall be made only 

to the extent authorized by, and in accordance with, the procedures in HHSAR 352.215-1 

(Instructions to Offerors—competitive acquisition).

(a) If authorized in agency implementing regulations, agencies may release proposals 

outside the Government for evaluation, consistent with the following:

(1) Decisions to release proposals outside the Government for evaluation purposes shall be 

made by the agency head or designee;

(2) Written agreement must be obtained from the evaluator that the information (data) 

contained in the proposal will be used only for evaluation purposes and will not be further

disclosed;

(3) Any authorized restrictive legends placed on the proposal by the prospective Contractor 

or subcontractor or by the Government shall be applied to any reproduction or abstracted 

information made by theevaluator;

(4) Upon completing the evaluation, all copies of the proposal, as well as any abstracts 

thereof, shall be returned to the Government office which initially furnished them for 

evaluation; and

(5) All determinations to release the proposal outside the Government take into consideration 

requirements for avoiding organizational conflicts of interest and the competitive 

relationship, if any, between the prospective Contractor or subcontractor and the 

prospective outside evaluator.

(b) The submitter of any proposal shall be provided notice adequate to afford an opportunity to 

take appropriate action before release of any information (data) contained therein pursuant to 

a request under the Freedom of Information Act (5 U.S.C. 552); and, time permitting, the 

submitter should be consulted to obtain assistance in determining the eligibility of the 

information (data) in question as an exemption under the Act. (See also Subpart 24.2, 

Freedom of Information Act.)
Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 3 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

3) Transmittal Letter

To Whom It May Concern:

Please accept the enclosed unsolicited proposal entitled, “Establishing a U.S. Center of 

Excellence for the Production of Key Starting Materials & Active Pharmaceutical Ingredients for 

Essential Medicines,” for your consideration. Kodak is proposing a comprehensive program 

intended to reestablish the capacity to manufacture Key Starting Materials (KSMs) and Active 

Pharmaceutical Ingredients (APIs) for certain essential drugs in the U.S.

The COVID-19 pandemic highlighted the severity of the country’s dependency on non-domestic 

sources for the majority of its pharmaceuticals, which resulted in potential drug shortages. It is 

critical to realign the current supply chain to guarantee a strong stockpile of treatments during the 

current pandemic and to minimize the country’s dependence on foreign sources for future needs. 

This realignment could be accomplished by expanding the country’s domestic manufacturing 

capabilities to produce a strong and dependable supply of critical pharmaceutical materials in the 

United States.

Kodak already possesses many assets and significant expertise to update and expand its 

Rochester, New York, facilities which would serve as a primary manufacturing hub for 

pharmaceutical starting materials, intermediates and APIs. This proposal outlines a strategy to 

create a robust manufacturing center capable of developing, testing, and producing a wide range 

of APIs that would allow the U.S. to be cost competitive. By expanding Kodak’s existing facilities 

and incorporating continuous manufacturing and advanced technology capabilities, the company 

could increase its capacity and provide the essential drugs needed for the American people. This 

would enable Kodak to serve as a strong and sustainable U.S. supplier now and in the future.

We look forward to discussing how Kodak can assist the U.S. Government with this effort.
Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 4 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

4) Table of Contents

Table of Contents

1) Cover Page.................................................................................................................... 1

2) Government Notice for Handling and Submitting Proposals.................................... 2

3) Transmittal Letter......................................................................................................... 3

4) Table of Contents ......................................................................................................... 4

5) Executive Summary ..................................................................................................... 5

6) Introduction .................................................................................................................. 6

7) Statement of Work.......................................................................................................10

8) Technical Approach Summary ...................................................................................14

8.1 CLIN 1: Procurement and Storage of KSMs for Essential Medicines in Shortage ...........15

8.2 CLIN 2: Establish U.S.-Based Production of KSMs for Essential Medicines in Shortage 17

8.3 CLIN 3: Establish Strategic Regulated KSM and API Ingredient Reserve (SAPIR) Facility

20

8.4 CLIN 4: Establish U.S-Based Advanced Manufacturing Capability for Regulated KSMs 

and APIs ....................................................................................................................................23

Associated Processes................................................................................................................35

8.5 CLIN 5: Establish a R&D Center of Excellence for Process and Analytical Test 

Development to Support Continuous Manufacturing and Testing of KSMs and APIs .................37

8.6 CLIN 6: Establish a Diagnostic Reagent Manufacturing Laboratory................................39

9) Project Management and Project Meetings...............................................................40

10) Global Logistics at Kodak...........................................................................................42

11) Program Management at Kodak.................................................................................42

12) Quality Systems at Kodak...........................................................................................45

13) Workforce Development .............................................................................................46

14) Key Personnel .............................................................................................................47

15) Organizational Chart- Kodak Pharma ........................................................................48
Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 5 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

5) Executive Summary

The United States imports the majority of its starting materials, intermediates and Active 

Pharmaceutical Ingredients (APIs), which are the main components of finished drug products. 

Only 12% of these materials are manufactured within the country for the U.S. market today. A 

variety of factors have caused this shift over several decades including labor costs, significant 

capital investments, and regulatory requirements.

Eastman Kodak Company has a well-established Specialty Chemicals business in Rochester, 

New York, located within a 1,200-acre industrial park, which includes 13 miles of rail, a 117

megawatt powerplant, and its own wastewater facility. By expanding its current facilities, the 

company is well-positioned to serve as a strong manufacturing hub in the U.S. 

Kodak proposes to mitigate the risks associated with offshore pharmaceutical manufacturing by 

applying the following principles: 

• Secure the upstream supply chain – focus on specialized equipment that would enable 

the production of key starting materials in the U.S., reducing the country’s dependence on 

raw materials from foreign sources, especially for Essential Medicines of Strategic 

National Importance.

• Reduce production costs— incorporate advanced manufacturing technologies, 

including continuous platforms and processes, in order to enable the long-term, 

sustainable production of starting materials, intermediates and APIs that improve yields, 

reduce waste, and reduce production costs.

• Formulate a public-private partnership – collaborate with the Federal Government and 

its partners to select products aimed at improving health outcomes and managing 

disruptions that may occur due to trade, natural disaster or public health threats.

Using these principles, Kodak proposes to establish a U.S. Center of Excellence for the 

Production of Key Starting Materials & Active Pharmaceutical Ingredients for Essential Medicines 

with four main components: 

1. Supply Chain Partner for Key Starting Materials (CLIN1, CLIN 2)– work with the 

Federal Government and its partners to determine key starting materials of strategic 

national importance for API manufacturing to ensure long-term supply chain resiliency. 

Kodak will begin by procuring and producing starting materials needed to support API 

production used in COVID-19 finished medicine products. This initiative includes 

manufacturing bulk intermediates as well as compounds for COVID-19 related 

treatments, and as supporting the development of a reserve of KSMs in preparation for 

future surges and shortages. For the long-term, Kodak will incorporate new technologies, 

which involve hazardous and specialized manufacturing capabilities (e.g. nitrations and 

hydrogenations) utilizing continuous manufacturing technology. This will enable the 

production of more starting materials and intermediates within the U.S.
Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 6 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

2. API Manufacturing Facility (CLIN 3, CLIN 4) — leverage existing infrastructure, 

including updating a Specialty Chemicals building to create an advanced hybrid 

manufacturing facility that combines existing batch manufacturing equipment with new 

continuous manufacturing processes. This upgraded facility will have the capacity to 

manufacture up to metric tons of API per week. Kodak proposes to construct a 

Strategic Active Pharmaceutical Ingredient Reserve (SAPIR) Facility that will benefit the 

nation by providing an insurance policy against potential interruptions in the U.S. API 

supply chain used for Essential Medicines. 

3. API R&D Center of Excellence (CLIN 5) – leveraging existing expertise, upgrade 

Kodak’s Research & Development (R&D) facility and focus on innovation and 

improvement of continuous manufacturing solutions to support essential medicine 

manufacturing for the United States. 

4. Reagent manufacturing facility (CLIN 6)- upgrade existing laboratories for diagnostic 

testing, to include GLP manufacture of bulk reagents required for diagnostic production 

as well as, long term, an assay research and development capabilities.

6) Introduction

The U.S. is critically dependent on foreign countries for starting materials, intermediates and 

Active Pharmaceutical Ingredients (APIs), which are the key components of final drug products. 

According to the Food and Drug Administration (FDA), in 2018, 88% of manufacturers producing 

APIs for the U.S. market were located outside of the country1. 

Kodak has the manufacturing equipment and infrastructure to make non-cGMP starting materials 

and intermediates at its 1,200-acre industrial site, which includes high temperature reactors and 

a trained labor force. With assistance from the U.S. Government, Kodak can expand its existing 

facilities and laboratory space in order to serve as a key U.S. supplier of starting materials, 

intermediates and APIs. Kodak’s existing manufacturing and lab space can be updated, shovelready land is available for expansions, and existing on-site utilities (e.g. rail, powerplant, 

wastewater facility, etc.) make the Kodak location a strong and economical choice when 

identifying current manufacturers well-positioned to expand in the U.S. 

There are many factors that led to the erosion of pharmaceutical API manufacturing in the U.S. 

over the last several decades. A recent FDA study analyzing drug shortages cited several 

economic challenges ranging from the lack of incentives to logistic and regulatory challenges. As 

1

FDA Drug Shortages Task Force. (2019). Drug Shortages: Root Causes and Potential Solutions. Retrieved from 

https://www.fda.gov/media/131130/download.

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting 

Materials & Active Pharmaceutical Ingredients for Essential Medicines 

Page 7 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

a result, 79% of the manufacturers producing APIs for 370 of the treatments on the World Health 

Organization’s Essential Medicines list are located outside the U.S.2

The common approach for API manufacturing is typically referred to as small molecule synthesis. 

These chemistries are typically conducted in batch manufacturing processes that are extremely 

labor intensive. The impact of the difference in labor costs coupled with the costs to responsibly 

manufacture hazardous chemistry, especially as it relates to treatment of effluents, drives up the 

current domestic manufacturing costs. 

In order to effectively shift API manufacturing back to the U.S., companies will need support from 

the U.S. Government to overcome many of these barriers that make it difficult for manufacturers 

to produce starting materials, intermediates and APIs in the U.S. compared to low-cost 

manufacturing countries such as China or India. 

The immediate and sustainable response plan has been defined in the below workstreams to 

provide for a comprehensive solution:

1. Procurement and Storage of KSMs for Essential Medicines in Shortage

2. Establish U.S.-Based Production of KSMs for Essential Medicines in Shortage

3. Establish Strategic API Ingredient Reserve (SAPIR) Facility

4. Establish U.S-Based Advanced Manufacturing Capability for KSMs and APIs

5. Establish a Center of Excellence for Continuous Manufacturing and Testing of KSMs and 

APIs

6. Establish a Diagnostic Reagent Manufacturing Facility

7. The Option to Establish a Formulation and Aseptic/Sterile Fill and Finish Facility for the 

Manufacture and Packaging of Final Drug Product

The immediate and sustainable response plan has been defined in the below workstreams to 

provide for a comprehensive solution (Table 2). The activities and timelines for each of the 

workstreams is shown in Figure 1.

2

Safeguarding Pharmaceutical Supply Chains in a Global Economy: Hearing Before the House Energy and Commerce Subcommittee on Health, 116 

Congress (2019) (Statement of Janet Woodcock). 

Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active Pharmaceutical Ingredients for 

Essential Medicines 

Page 9 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Figure 1: Program Overview

WBS Task 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

1 Procurement and Storage of KSMs for Essential Medicines in Shortage

1 2 Procurement of KSMs

1 3 Storage of KSMs

2 Establish U.S.-Based Production of KSMs for Essential Medicines in Shortage

2 2 Development of KSM manufacturing processes

2 3 Manufacture of KSMs

3 Establish Strategic API Ingredient Reserve (SAPIR) Facility

3 2 Construction of new storage facilities

3 3 Procurement of new equipment

3.4 Establish compliant materials handeling systems

4 Establish U.S-Based Advanced Manufacturing Capability for KSMs and APIs

4 2 Rnovation/construction Building 

4 3 Validation of new facility

4.4 Manufacture of API (Startup cost)

4 5 Construction of Starting Material Facility #1 (hydrogenation)

4.6 Construction of Starting Material Facility #2 (nitration)

5

Establish a Center of Excellence for Continuous Manufacturing and Testing of KSMs and 

APIs

5 2 Renovation of existing manufacturing facilities

5 3 Purchase of essential equipment

5.4 Commissioning of CoE

5 5 Process Development- outsourced (15 Compounds)

5.6 Transfer of continuous KSM manufacturing processes

5.7 Process Development CoE

6 Establish a Diagnostic Reagent Manufacturing Facility

6 2 Renovation of existing manufacturing facilities

6 3 Procurement of new equipment

6.4 Establish compliant manufacturing and testing systems

6 5 Manufacture of diagnostic reagents

6.6 Storage of diagnostic reagents

2020 2021 2022 2023 2024

(b) (4) (b) (4)




Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 14 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

8) Technical Approach Summary

Why Kodak?

Eastman Kodak Company (Kodak) offers pharmaceutical manufacturers a unique combination 

of skills and resources needed to quickly commence production and distribution of products that 

meet the highest standards: a well-established culture of innovation, extensive ready-now 

infrastructure and deep experience in intricate manufacturing and supply chain management. 

Kodak, founded in 1888 and operating publicly for over 117 years, is an iconic American 

company with a globally recognized brand, and is viewed as one of the most innovative 

companies in the areas of material sciences and chemistry. As an American company that has 

participated in bringing about technological innovations that have changed the way Americans 

live, Kodak wants to do its part to strengthen the U.S. supply chain for the pharmaceutical 

industry to ensure the American population can remain protected and healthy.

Kodak’s Eastman Business Park is located on a 1,200-acre campus with 16 million square feet 

of manufacturing, lab, warehouse and office space. To support pharmaceutical manufacturing 

and distribution, the Park offers built-in, cost-efficient utilities (including an on-site 117 MW

power plant and access to a 2,400 gallon-per-minute de-mineralized water supply); convenient 

access to transportation (including 13 miles of rail track within the Park and close proximity to 

the interstate highway system and an international airport). This infrastructure allows Kodak to 

have speed to market as well as competitive labor and capital costs. This is recognized by the 

fact that EBP houses world renowned healthcare and biotech companies, including: Dupont, 

Carestream, Ortho Clinical Diagnostics, Greenlight Biosciences, and Aedicell. Lastly, Kodak is 

one of the few companies that has a fully integrated infrastructure to take a new product from

lab scale to production pilot to full manufacturing all within the same organization.

Kodak currently employs hundreds of people in within Specialty Chemicals business ranging

from chemists and engineers to technicians and chemical operators. The vast majority of these

employees have over 20 years of experience. In addition, the Greater Rochester region is wellknown for its superior academic institutions and workforce development programs. Today, more

than 2,100 people in the area currently work within the pharmaceutical industry. 

Kodak’s century of science has resulted in more than 20,000 U.S. patents ranging from roll films

to the invention of the digital camera, inkjet pigmented inks, and process-free digital plates. In 

addition to its well-known film business, the Company has over the decades adapted its 

fundamental expertise in material science and chemistry to participate in a variety of industries, 

including organic chemicals manufacturing, clinical diagnostics, space imaging and printing and 

publishing. In the area of digital printing, Kodak has extensive experience with digital printing on 

a wide range of packaging applications for pharmaceuticals.
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 15 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Kodak also has world renowned expertise in both manufacturing, logistics and supply chain 

management. Worldwide distribution of Kodak products is managed out of 35 warehouses in 18 

countries. Domestic U.S. distribution centers are in Columbus Georgia, Dayton Ohio, City of 

Industry California, and Rochester, New York. Kodak’s manufacturing, logistics and supply 

chain have been entirely unaffected by the current pandemic. Kodak was deemed an essential

business from the start of the pandemic, so it continued to manufacture to meet customer

demands. Through a combination of existing safety stock inventory and excellent procurement

management, the company continuously purchased the raw materials required for its

operations.

Kodak continues its commitment to research and development, with recent innovations 

including silver-based antimicrobial coatings, engineered micro-particle technology, and highresolution functional printing used to print elements of touch screens, antennas, sensors and 

more including security measures for pharmaceutical packaging (e.g. RFID, Embedded Data, 

etc.). 

Kodak has a long history of supporting the U.S. Government. Kodak has been a supplier of a 

variety of films to the government during wartime, Cold War, and peacetime for use in military 

and U.S. security as well as films for NASA. Whether it was providing aerial lenses, cameras or 

optics for tank periscopes during the second World War or providing sensors or cameras for 

several of NASA’s space missions, Kodak has been serving as a strong partner of the U.S. 

Government for over a century. 

With the entrepreneurial passion and agility of a startup and the institutional knowledge and 

infrastructure of a giant, Kodak is prepared to be an invaluable partner for America’s 

pharmaceutical industry. 

8.1 CLIN 1: Procurement and Storage of KSMs for Essential Medicines in Shortage

Procurement of KSMs (WBS 1.2)

Storage of KSMs (WBS 1.3)

Kodak proposes to immediately begin efforts to secure a supply of essential KSMs and their 

precursors, while working to bring the manufacturing of these, and other, essential KSMs back 

to U.S. soil. Kodak will do everything possible to support this effort. An inventory for a large 

strategic stockpile will be established in the follow steps.

Specialty Chemicals Warehouse is a full-service storage, logistics and distribution center. 

There are two warehouses located in Eastman Business Park in Rochester, NY. Product from 

these warehouses can be shipped to Kodak Regional Distribution Centers or directly to 

customers World-Wide. The warehouses consist of sections capable of storing chemicals at 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 16 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

controlled room, refrigerated or frozen temperatures. Storage abilities include high hazard, low 

hazard and work in progress.

Specialty Chemicals Warehouse utilizes square feet in This facility is certified 

as a NYS chemical storage facility. Additionally is a square foot facility that is 

NYS certified for high hazard chemical storage. An advanced SAP MRP system is used for 

inventory management. Kodak is fully compliant with all SOX regulations. All materials are lot 

traced and tracked through PV Suite III software. The warehouses are managed under an ISO 

9001- 2015 quality system, an ISO 14001 HSE system and a Lean Production Management 

system. There is 24-hour monitoring security. The warehouses are CFAT (Chemical Facility 

Anti- Terrorism) Compliant. Both warehouses are designated as Foreign Trade Zones and 

compliant with U.S. Customs, A.T.F. & Homeland security agencies requirements. There is 

segregation and isolation capability within the facilities. Kodak is certified to ship HazMat 

materials both domestically and for export. Kodak will establish a controlled stockpile of KSMs 

as quickly as possible by procuring these compounds from existing manufacturers. These 

vendors will be qualified and audited if necessary. 

The following are examples of the potential KSMs that Kodak will procure (and store) in addition 

to their precursors. The majority of these are not currently manufactured or stored in the U.S. 

Precursors purchased under CLIN 1 will be used in KSM manufacturing in CLIN 2.

1. 2-Chlorophenyl cyclopentyl ketone CAS 6740-85-8 (Ketamine KSM)

2. 3-(4-Hydroxyphenyl)propanoic acid methyl ester (Esmolol KSM)

3. 1-(2-Phenethyl)-4-piperidinone (Fentanyl KSM)

4. 5-[[(1,1-Dimethylethyl)amino]acetyl]-2-hydroxybenzaldehyde (Salbutamol KSM)

5. 3,4-Dihydroxy-α-isopropylaminoacetophenone (Isoproterenol KSM)

6. 2-Amino-3',4'-dihydroxyacetophenone (Norepinephrine KSM)

7. 2,4-Dichlor-5-(chlorosulfonyl)benzoic acid (Furosemide KSM)

8. (2-Furanylmethyl)amine (Furosemide KSM)

KSMs selected and procured for the initial stockpile will be stored in the renovated warehouse 

under controlled room temperature, humidity, light exposure, and access. It will be equipped 

with advanced inventory management technology and managed under an FDA Part 11 

compliant validated Warehouse Management System.

Kodak proposes to immediately begin efforts to secure a supply of essential KSMs, while 

working to bring the manufacturing of these, and other, essential KSMs back to U.S. soil. Kodak 

will do everything possible to support this effort. An inventory for a large strategic stockpile will 

be established in the follow steps:

This initial effort will be coordinated with the Public-Private partnership, in order to qualify and 

quantify the essential KSMs needed for initial and short-term acquisition and storage. The 

company has two existing warehouses in the business park, both or either of which can be 

equipped for the initial warehousing of KSMs. The warehouses include infrastructure 

requirements for temperature controls, tracking, segregation, and all ISO Lean (Six Sigma) 

(b) (4) (b) (4) (b) (4)(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 17 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Quality requirements. The initial stockpile will be procured from existing suppliers; will be 

subject to incoming RM testing and will be appropriately tracked, traced, and segregated in the 

secure warehouse space. Suppliers will be audited as necessary, if not previously qualified by 

the company.

8.2 CLIN 2: Establish U.S.-Based Production of KSMs for Essential Medicines in 

Shortage

Development of KSM manufacturing processes (WBS 2.1)

Manufacture of KSMs (Building ) (WBS 2.2)

Establishing US-based production of KSMs for Essential Medicines will involve upgrade and 

expansion of existing capabilities; Kodak currently produces such materials for pharmaceutical 

companies, Contract Manufacturing Organizations (CMOs) and small biopharma companies. 

The effort called for in this CLIN will be accomplished in building , where this production is 

currently taking place. The precise product mix which will be coordinated and agreed to 

between the Government and its partners in this initiative, to eliminate redundancy. 

The facility has sufficient capacity to produce metric ton quantities of these starting materials. In 

addition, a thorough review of policies, procedures, and processes will be made prior to initiating 

such manufacturing under this initiative. The company will ensure that its quality systems 

provide robust documentation and traceability procedures, as required by Good Documentation 

Practices, ISO standards, and critical RM vendors supplying starting materials for commercial 

pharmaceutical production.

Kodak Specialty Chemicals specializes in the synthesis and scale-up of complex heterocycles 

and specialty polymers. With over a century of experience in scaling up innovation, Kodak has 

built an extensive proprietary database of molecules and processes.

Kodak is a leader in contract manufacturing and custom chemical synthesis, and currently 

supplies raw materials to contract manufacturing organizations (CMOs) in the pharmaceutical 

space. Kodak is considered the preferred supplier for a major pharmaceutical CMO and 

provides starting materials for its generics and for its Phase I, Phase II and Phase III trials. 

Kodak also supplies starting materials to innovator pharmaceutical companies for early phase 

trials. 

The existing facility (Building is already equipped with reaction vessels, centrifuges 

and dryers for a total of of capacity.

Initial KSMs of interest will include those that help support complete U.S. domestic 

manufacturing initiatives, such as the public-private partnership with Kodak.

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4 (b) (4 (b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 18 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

A representative list of potential starting materials is included. Kodak will also work with partners 

such as to ensure the materials that are procured are not redundant. Kodak’s analysis of 

the proposed synthetic pathways is described for the list of identified KSMs. 

(b) (4)

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 19 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 20 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Kodak Specialty Chemicals which specializes in the synthesis and scale-up of complex 

heterocycles and currently a supplier of starting materials to Pharmaceutical contract 

manufacturing organizations and innovator pharma companies, will provide a safe and secure 

supply of critical KSMs for use and stockpile. 

8.3 CLIN 3: Establish Strategic Regulated KSM and API Ingredient Reserve (SAPIR) 

Facility

Construction of new storage facilities (WBS 3.2)

Procurement of new equipment WBS 3.3)

Establish compliant materials handling systems (WBS 3.4)

Kodak is proposing a to construct a Strategic Active Pharmaceutical Ingredient Reserve 

(SAPIR) Facility that will benefit the nation by providing an insurance policy against potential 

interruptions in the U.S. Regulated KSM and API supply chain used for Essential Medicines. A 

release of Regulated KSMs and APIs from the SAPIR will be able to mitigate the potential 

damages from disruption in international or domestic pharmaceutical ingredient supply and the 

accompanying risk to the healthcare system and rapid price increases. This facility, when 

completed, will have the capacity to house inventory of Regulated KSMs and APIs produced on 

the Kodak campus, Regulated KSMs and APIs acquired from third parties, and additional 

Regulated KSMs and APIs of strategic interest, which may be required to be stored for the U.S.

Government. This SAPIR will coordinate strategies with other SAPIR (including ) facilities

to prevent unnecessary redundancy and yet provide resilience to the supply chain.

Key elements of this CLIN are as follows:

The SAPIR will be located at Kodak’s site in Rochester, NY. Kodak has several parcels 

available at the Eastman Business Park as illustrated below. Prior to that point, Regulated 

KSMs and APIs would be stored in a temporary warehouse also at the Eastman Business Park 

site. 

The SAPIR will include advanced security measures to ensure adequate protection of the 

Regulated KSMs and APIs in reserve. Kodak will work directly with the USG to finalize the plans 

for the security of this facility. Regulated KSM and API for the SAPIR will be stockpiled from 

batches being produced 1) as a part of the COVID-19 efforts, 2) when manufacturing additional 

Regulated KSMs and APIs to support commercial needs, and 3) will be procured by Kodak 

when Regulated KSMs and APIs of interest are available to be acquired from foreign sources. 

The USG, at its option, may also choose to procure and have Kodak store Regulated KSMs and 

APIs of strategic interest for national health security.

The inventory will all be managed by Kodak; however, inventory owned by the USG will require 

direction regarding length of storage and stability requirements. Regulated KSM and API will be 

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 21 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

transported to the SAPIR either directly on-site from batches manufactured in Rochester, NY, or 

through standard supply and distribution networks. Kodak will maintain its own Quality Systems 

for the SAPIR and will oversee the shelf life of the Regulated KSM and API through an ICH 

stability and stock rotation program for the APIs to ensure the stock is kept within FDA shelf-life 

limits. The inventory and quality management program for the SAPIR will include, at a minimum, 

the following elements:

• Conducting routine quality assurance on all products

• Performing annual inventory of all products

• Inspecting environmental conditions, security, and package maintenance

• Ensuring the ability to transport items during a public health emergency

• Tracking the expiration date and manufacturer lot numbers of eligible products

• Inventory Management and Tracking System

• Coordinating the shipment of products to FDA for stability testing

• Receiving and tracking FDA testing results for each lot of product

• Disposing of and replacing product lots that have failed FDA testing

• An IT infrastructure, that includes FDA-level validation of the appropriate software 

system to manage the large and rapidly moving inventory

The SAPIR will also be managed under an FDA Part 11 compliant validated Warehouse 

Management System, under Current Good Manufacturing Practices (CGMP) with a qualityfocused team and will be ISO 9001:2015 certified.

The proposed SAPIR solution currently includes the following:

1) SF warehouse facility includes 6K SF office and 6 to 8 loading docks

2) Rectangular pre-engineered metal building with 30 foot clear to underside of structure

3) Existing as-builts of site utilities and existing foundations available, and assumed 

existing foundations are cut to 2 to 4 foot below grades, $400K allowance included to 

deal with obstructions or demolitions

4) Acceleration of 12-18 months construction time may lead to premium

5) Utility proximity for connection to site

6) Excludes any hazardous material removal. All soils from existing excavation/backfill to 

remain on site and subject to environmental easement

The proposed site at Eastman Business Park offers the following infrastructure:

• Full complement of on-site Utilities available (electric, steam, chilled & high purity water, 

compressed air, nitrogen, industrial sewer service and on-site wastewater treatment 

plant

(b) (4)

Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 23 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

8.4 CLIN 4: Establish U.S-Based Advanced Manufacturing Capability for Regulated 

KSMs and APIs

Renovation and construction of manufacturing facilities (Building (WBS 4.2)

Validation of New cGMP Hybrid Manufacturing Facility (WBS 4.3)

Manufacture of API (WBS 4.4)

Construction of Starting Material Facility #1- Nitration (WBS 4.5)

Construction of Starting Material Facility #2- Hydrogenation (WBS 4.6)

Kodak will manufacture the required Regulated KSMs and synthesize the APIs as required by 

the USG; a surplus of both will be produced. Both Regulated KSMs and APIs will be stored in a 

secure, environmentally-controlled warehouse. All equipment and utilities will be 

qualified/validated, as appropriate. Regulated KSMs will be produced under a Quality System 

utilizing Kodak’s existing ISO controls and Good Documentation Practices (GDP) to provide 

100% traceability and to streamline integration throughout the processes. Regulated KSMs and 

APIs will be produced in a new facility and made under ICH Q7 GMPs for Active Pharmaceutical 

Ingredients, both for batch manufacture and continuous manufacturing. Any electronic data 

capture regulated by 21 CFR Part 11 will be Part 11-compliant. New equipment will be 

purchased, qualified/validated as appropriate. For high-risk processes such as nitration and 

hydrogenation two separate buildings will be constructed. As these are exothermic reactions, 

the heat can be captured and used for heating the building or the water supply.

Approximately $48M will be saved by converting approximately m3 of existing reactor 

capacity to cGMP compliant manufacturing. Along with new construction, total cGMP reactor 

manufacturing capacity will be approximately m3 with capability of manufacturing between 

Metric Tons of API per year.

Locating new Hybrid facility and specialized starting material capability near existing capacity 

will allow for less costly tie to site infrastructure (water supply, sewer, waste handling).

(b) (4) (b) (4) (b) (4) (b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 24 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Figure 3. Building and the new Hybrid facility

Building Upgrade to cGMP Standards

Project Scope

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 25 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Building

(b) (4)

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 26 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Hybrid cGMP Manufacturing Facility

A Hybrid manufacturing facility will be built on the same site to expand the manufacture of 

Regulated KSMs and APIs using advanced technologies to lower costs and expand the supply 

chain. The new Hybrid Manufacturing Facility will connect to and extend west of Building 

Project Scope

The conceptual design for the HMF is based on existing, proven API manufacturing technology 

which when coupled with the upgrades of the existing Building equipment will allow for 

production of multiple APIs simultaneously. 

This new two-story building will accommodate reactor and filter-dryers. Together with 

Building , the combined facility will have approximately m3 of reactor capacity capable 

of manufacturing MT of various APIs per year. The facility will include all utilities to operate 

the infrastructure but will leverage the existing cold room storage, in-process testing laboratory, 

environmental monitoring laboratory, offices and administration area. 

Existing and proven design specifications for reactor systems will be used to expedite the 

procurement of long lead items.

Building

The design criteria employed on the project is defined below and will be in accordance with the 

requirements of the applicable codes and standards. The proposed building will be a two-story 

(b) (4)

(b) (4) (b) (4) (b) (4(b) (4) (b) (4) (b) (4) (b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 27 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

approximately sq ft facility and will be constructed as a rated structure for hazardous 

manufacturing. The exterior envelope will be an insulated vent panel system appropriate for the 

climate.

There will be insulated dock and equipment doors at the perimeter and painted hollow metal 

door assemblies other than in the administration area. The roof construction will be a gray 

EPDM over foam insulation on metal decking.

The overall building layout will support production of multiple APIs. The building will be 

connected to Building to leverage existing assets and improve material flow. Controlled 

gowning entries will be provided to maintain general cGMP (Good Manufacturing Practice) 

areas. Gowning areas will be provided per ISO clean room standards

From the first floor, raw materials can be staged for production, charging of materials from the 

tank farm and other manipulations and transfers can occur.

Figure 5. New Hybrid cGMP Manufacturing Facility (2 floors/ sq ft)

There will be large charge booths where materials can be charged in a safe manner and to 

prevent any contamination. There will be areas for operators to document the process as well 

(b) (4) (b) (4)

(b) (4)

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 28 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

as control the equipment at both levels. No additional office space will be present in this 

building as existing infrastructure will be utilized for this. Some engineering modifications will 

occur to the plans to enable the latest concepts for continuous manufacturing platforms.

Major Equipment

Major equipment will be a combination of glass-lined steel and Hastelloy reactors for the 

majority of the processing. Various support equipment such as pumps, filters, charging devices 

will be utilized to move material throughout the facility. In addition to this, filter dryers will be 

used to isolate and dry material.

Starting Material #1 Facility (High Pressure Hydrogenation, Halogenation Facility)

A manufacturing facility will be built to the west of the new Hybrid Manufacturing facility 

connecting to Building (existing high pressure manufacturing lab). The new facility will build 

on existing capabilities and will be used for specialized and more hazardous reaction 

chemistries including hydrogenation, halogenation, and ethylene oxide chemistries 

Project Scope

This new facility will meet cGMP requirements and will include the following:

• and gallon reactors systems

• Filtration equipment

• Drying Equipment

• Preweigh Equipment

• Hydrogen storage and compressors

• Scrubber system

• High purity Water system

• Parts cleaning equipment

Building

The design criteria employed on the project is defined below and will be in accordance with the 

requirements of the applicable codes and standards. The proposed building will be 

approximately sq ft and will be specially designed with blast resistant walls for hazardous 

manufacturing. 

The building will include the following:

• Production bays

(b) (4) (b) (4) (b) (4) (b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 29 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

• Loading Dock

• Personnel areas

• Gowning areas

• Parts cleaning area

The new facility will support manufacturing from the combined upgraded Building and the 

new Hybrid manufacturing facility.

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 30 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Figure 6. Starting Material Facility #1, High Pressure Hydrogenation, Halogenation, Other 

Hazardous Chemistry

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 31 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Starting Material Facility #2 (Nitration Facility)

An additional manufacturing facility will be built to the south and west of the new Hybrid 

Manufacturing facility. The new facility will be used for additional hazardous reaction 

chemistries including Nitrations. 

Project Scope

Similar to Starting Material Facility #1, this new facility will include the following:

• gallon reactors systems

• Filtration equipment

• Drying Equipment

• Preweigh Equipment

• Acid storage + spent acid tanks

• Scrubber system

• High purity Water system

• Parts cleaning equipment

Building

The design criteria employed on the project is defined below and will be in accordance with the 

requirements of the applicable codes and standards. The proposed building will be 

approximately sq ft and will be constructed as a rated structure for hazardous 

manufacturing. The exterior envelope will be an insulated vent panel system appropriate for the 

climate.

The building will include the following:

• Production bays

• Loading Dock

• Personnel areas

• Gowning areas

• Parts cleaning area

The new facility will support manufacturing from the combined upgraded Building and the 

new Hybrid manufacturing facility.

(b) (4) (b) (4) (b) (4) (b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 32 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Figure 7. Starting Material Facility #2, Nitration, Other Hazardous Chemistry

(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 33 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Common to each of these installations:

HVAC (Heating Ventilation and Air Conditioning)

HVAC user requirements for the HVAC and support utility systems have been established to 

convey the overall intended approach to HVAC design and performance requirements and 

serve as the agreed basis for further defining the design and developing P&IDs, General 

Arrangement drawings and Equipment Lists. During a future design phase, individual 

specification documents for the equipment and systems will be developed for validation 

purposes. 

The validated cleanroom HVAC system will focus on controlling five (5) key variables: 

Classification, Pressurization, Air Handling Unit (AHU) Zoning, Temperature Control and 

Humidity Control. The design team will specify and design the facility air handling unit to meet 

cGMP (current Good Manufacturing Practices) requirements as outlined by the International 

Society of Pharmaceutical Engineering (ISPE) and the Food and Drug Administration (FDA) 

guidelines which is generally accepted to be defined by Title 21, Parts 210 and 211 of the Code 

of Federal Regulations. To consider this facility a cGMP facility, minimum critical environmental 

parameters must be achieved by the HVAC systems. 

Mechanical Utilities

Fire/industrial Water will be piped into the building from the existing line and used for fire 

preventative measures. Accompanying this will be dedicated retention areas to capture any 

discharged fire water.

Potable and Process Water design, installation, and operation will follow recognized industry 

practices to minimize bacteria formation, growth, and provide for system cleanability and 

sanitization. The water systems already exist at this location, so this new construction will tie 

into this existing infrastructure. Also used for safety fixtures such as safety showers and eye 

washes.

Gaseous Nitrogen is required for all of the equipment in the operations area to inert the 

operations since flammable solvents will be used. Gaseous nitrogen shall be supplied from an 

existing liquid nitrogen storage tank with evaporator.

Instrument and Clean Compressed Air will be used for instrumentation and general purposes 

and will leveraged from the existing infrastructure. 

Breathing Air will be used for the operations staff whenever they need to perform a unit 

operation in which they may be exposed to solvent vapors or low oxygen level conditions such 

as entering a reactor for cleaning.

Process Cooling will be used for cooling the equipment as well as some of the infrastructure 

within the building. This will be leveraged off of the existing supply.

Plant Steam will be supplied by the central utilities provider for the industrial site (low pressure 

and 70 psig steam). Plant steam loads include the processing equipment as well as building 

heat. 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 34 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Bulk and Drum Solvents will be provided from the existing infrastructure. Extension of pipelines 

from the tank farm will need to be installed, but no new tank storages are anticipated. There is 

sufficient warehouse space to support additional storage of drummed solvents.

Electrical will be supplied from existing load centers located nearby.

Sewer and non-hazardous aqueous waste system will be provided from the existing 

infrastructure which utilizes the on-site industrial wastewater treatment plant.

Emission Control is required for all emissions from the reactors and processing equipment. A 

new line will be run to tie into the existing thermal oxidizer on the site to treat all the air 

emissions.

Organic Waste will be handled through the existing infrastructure. New piping will be run to tie 

into the bulk waste tank-farm that is located on the site. Any additional waste that needs to be 

handled through drummed waste will be stored in the existing drum storage designated for 

waste and is removed through a third party contractor to be incinerated.

Solvent Recovery – All recyclable solvents will be collected and transferred via an existing 

pipeline to central distillation plant located on the industrial site.

cGMP Material Flow

Process Flow starts in the existing warehouse where all raw materials are received, sampled 

and sent to the QC lab for testing. Once tested and reviewed, QA will print acceptance tags to 

be put on the raw material containers. Once approved, the warehouse staff can moved the 

materials into the staging area of the production facility. The operations staff will then charge 

liquids into the reactors through a polish filter and charge any solids using a solids charge 

feeder. This is all done in a closed system to maintain the integrity of the reactor and an inert 

atmosphere.

Once the reaction steps are completed, products will be transferred to either 

• a centrifuge through a closed system to isolate and wash the final product. This product 

is then transferred in a closed system into a separate charging device which will store 

the product as a wet-cake until it is ready to be charged to a dryer. 

• an agitated filter dryer

After completing the drying operation, the product is discharged into a large container or 

individual drums for final testing and release. 

Gowning Requirements and Personnel Flow

There will be multiple personnel flows based on operations. These operators will provide service 

for the operations and isolation of product. Specific gowning requirements for enter and exiting 

the final product areas are different and will be established. 

 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 35 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Equipment Qualification / Process Validation

Original equipment manufacturers (OEMs) will be utilized in association with site personnel to 

install, commission, and qualify (Installation Qualification, Operational Qualification, 

Performance Qualification) all cGMP related equipment. Factory Acceptance Tests shall be 

performed on all major pieces of equipment prior to shipment to the facility. Process 

engineering studies will be performed to determine and verify appropriate product batch sizes 

and scale-up requirements. A site Validation Master Plan will be developed and approved as the 

overall governing document for the site’s validation approach. As part of the overall validation 

process, FMEAs (Failure Mode and Effects Analysis) and Risk Assessments will be performed.

This will include identification of Critical Quality Attributes (CQA) and Critical Process 

Parameters. Qualification (water runs) will be initially performed in testing the equipment and 

processes. Media fill runs will be performed to represent all product container/closure 

configurations and volumes for final line qualification.

Associated Processes

DMFs (Drug Master Files) for specific products will be developed utilizing internal resources but 

may also include purchasing existing DMFs from existing manufacturers. This will also include 

development of DMF submission documents. Ownership of the DMFs will provide more control 

and flexibility over commercial manufacturing. 

Analytical Methods and Assays will be developed and validated as part of the overall product 

development and technical transfer processes. Development of Validation Protocols for 

analytical and assay methods will include aspects of product manufacturing control, 

performance, and product stability indication, etc. and will be developed consistent with the 

overall site Validation Master Plan. Testing will include identity, purity, potency, and stability of 

the bulk drug substance and final drug product in accordance with ICH Standards. 

Product Stability Testing will be completed during the product development process and will 

include both external and site personnel for completion. Design of stability testing plan and 

conduct of stability studies on bulk and final product will be completed through the externally 

contracted product development process.

Product Release and Routine Stability Testing of bulk drug substance will be conducted via 

onsite laboratories and the site Quality Unit in accordance with ICH Stability Standards. 

Sufficient storage for both cold chain and controlled drug products will be built or utilized 

between on-site facilities to accommodate routine stability testing requirements.

Regulatory Inspection activities, including Food and Drug Administration, Drug Enforcement 

Administration, Occupational Safety and Health Administration, etc. will be managed through 

the site Quality Unit in conjunction with other personnel.

Controlled Drugs and Cold Chain Products will have procedures in place to allow appropriate 

allocations, handling, storage, fill-finish operations, and final release and distribution.

Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 37 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Starting Material Facilities will allow for domestic manufacture of these functionalized starting 

materials that currently do not have a domestic supply. 

Continuous manufacturing will provide a way to safely execute the above-mentioned hazardous 

chemistries and transfer these functionalized starting materials to the batch manufacturing wing 

to manufacture the KSMs and APIs. 

Establishing an in-house supply by backward integrating to the functionalized starting materials 

positions Kodak to manufacture KSMs and API in the U.S. without being dependent on nondomestic sources and supply constraints.

8.5 CLIN 5: Establish a R&D Center of Excellence for Process and Analytical Test 

Development to Support Continuous Manufacturing and Testing of KSMs and APIs

Renovation of Existing Manufacturing Facilities (WBS 5.2)

Procurement of Essential Equipment (WBS 5.3)

Commissioning of R&D Center of Excellence (WBS 5.4)

Process Development- Outsourced (WBS 5.5)

Transfer of Continuous Manufacturing Processes for KSMs (WBS 5.6)

Process Development in R&D Center of Excellence (WBS 5.7)

A crucial activity for success of manufacturing starting materials, intermediates and APIs for the 

pharmaceutical industry is the development of manufacturing processes for both batch reactors 

and continuous manufacturing vessels. Continuous processing methodology has come into 

favor, especially for small molecule compounds, because it is more efficient than batch 

methods, which require frequent interruptions in the process to conduct in-process testing of the 

product for purity, potency, etc. 

Therefore, continued development activities are intended to provide optimum processes for 

manufacturing at scale, to achieve high yields, potency and purity, high quality, and lower cost 

as materials are made at production/commercial scale. Kodak intends to establish, by 

renovating an existing R&D facility, a “Center of Excellence” to support the continued 

development and optimization of continuous manufacturing processes (as well as batch 

processes where required) for both KSMs and APIs. High quality and purity are assured by also 

providing for continuous testing of these materials and APIs at key points throughout the 

process, and this is an activity that benefits as well from methodologies developed in the lab.

For over 100 years, Kodak has been a leader and innovator in materials science. Kodak as an 

inventor and innovator has been awarded over 20,000 U.S. patents in the last century with 

many of them in new materials, materials formulations, and integration of materials into useful 

articles across imaging, printing and healthcare industries. The demonstrated R&D capability 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 38 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

and results are not only reflected in U.S. patents, but also in a wide range of technical and 

scientific articles published in peer-reviewed journals.

This expertise encompasses the following: 

• Invention of new materials for a variety of functions and applications; 

• Formulation of these materials into useful compositions such as color negative films, 

inkjet inks, electrophotographic toners, antimicrobials, offset digital printing plates, and 

more; and, 

Process development in order to scale materials and material formulations into tens of 

thousands of kilograms per year.

It is this experience and demonstrated capability Kodak brings to the task of process 

development for pharma materials.

In the Center of Excellence, Kodak will investigate the range of materials noted above to 

develop the manufacturing processes for such materials that exist today and to develop 

processes for new materials being invented well into the future. It is expected the Kodak Center 

of Excellence will optimize existing synthetic routes for starting materials, intermediates, and 

APIs, and explore and develop alternative routes for large scale manufacturing. This has been 

demonstrated for batch reactors and will be an important aspect of process development for 

advanced manufacturing of pharma materials through continuous manufacturing processes. 

The location of the Center of Excellence in the Kodak Research Labs (KRL) ensures the facility 

will be co-located within Eastman Business Park with the manufacturing facilities for the pharma 

materials. This enables ready, in-person interactions to ensure compatibility of developed 

synthetic processes with manufacturing facilities and capability, as well as inclusion of “design 

for manufacturability” (DFM) principles for optimizing yield, quality, and cost. 

KRL includes existing laboratory space that would require facility and equipment updates 

outlined in Figure 5.


Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 41 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Kodak will conduct strategic meetings at least once per year to discuss overall project design, 

progress, and performance. These meetings will focus on technical progress and performance 

according to the IMS and budget.

Meeting Schedule

Kodak will develop a schedule for internal (Kodak and partners only) and external (Kodak and 

USG) project meetings that are designed to ensure collaboration between USG and Kodak on 

areas of mutual interest and progress towards the project objectives. 

Project teams will meet with USG regularly (e.g., biweekly) via teleconference to report on current

activities, risks, issues, and planned activities. Teleconferences are designed to ensure continual 

communication and collaboration between Kodak and USG on all project activities. 

Routine Reporting

For each CLIN, Kodak will provide the following project deliverables:

• Regular (Biweekly or Monthly) Project Team Meetings

• Monthly Invoice

• Monthly Financial Report

• Monthly Technical Report

• Annual USG Strategic and Programmatic Review Meeting

• Other Deliverables as required

• FDA interactions, ad-hoc meetings, protocols reports, publications, inventions

Subcontractor Management

Kodak will develop a subcontractor management plan defining roles and responsibilities among 

Kodak and its subcontractors. Regular meetings will be scheduled with each of the 

subcontractors to track the progress of the subcontractors. Subcontractor technical progress, 

cost and risk will be regularly updated to keep the project on schedule and within budget and to 

mitigate risks. Diligent manufacturing and quality oversight are essential to this program. A 

person-in-the-plant will be used to monitor manufacturing activities and quality audits will be 

conducted, as applicable.

Risk Management

Kodak will identify, track, and respond to risks as they are identified. The individual project 

teams track and manage risks identified in a Risk Register that assesses the probability and 

impact of a specific risk to establish its severity. The management team will collect, sort, and 

aggregate the risks for reporting to the USG. All risks will be assessed according their potential 

impact on the project goals.
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 42 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

10) Global Logistics at Kodak

Kodak Logistics is responsible for distribution warehousing, transportation and international 

trade compliance. Worldwide distribution of Kodak products is managed out of 35 warehouses 

in 18 countries. Domestic U.S. distribution centers are in Columbus Georgia, Dayton Ohio, City 

of Industry California, and Rochester, New York. Products stored in these warehouses include 

chemicals, film, inks, toners, printing plates, printing machines and spare parts. Due to the 

requirements of Kodak’s products, the warehouses are temperature controlled. Kodak moves 

over two million kilograms of freight per month and uses virtually all modes of transportation. 

Kodak has well-established partnerships with many of the country’s largest transportation 

companies and has experience transporting both hazardous and non-hazardous freight.

Kodak is a self-filer for both export and import entries with U.S. Customs. The company 

maintains a secure supply chain and, as a result, has earned C-TPAT Tier III certification. 

Additionally, our carriers and 3PL partners were selected, in part, based on also having 

achieved C-TPAT certification. 

11) Program Management at Kodak

Our Program Management has two elements- one is Capital Program Management the other is 

the New Product Commercialization Management. 

Kodak outsources its Capital Program Management to

is an established partner that has a strong working relationship with Eastman Kodak that 

goes back many decades. Fourteen years ago acquired the engineering and construction 

divisions of Kodak and entered into an exclusive agreement to provide capital project services 

for Kodak. also expanded its client base for the use of these acquired skills and has 

provided program management, engineering, design and construction services for many 

chemical, food and pharmaceutical companies in addition to Kodak. Clients include Dupont, 

Lonza, Arkema, Thermo Fisher/Life Technologies, Regeneron, Carestream and 

AstraZeneca. has an engineering and project management team of 100. In addition to 

EPC services, program & project management, maintains a skilled trades workforce with 

over 100 industrial tradesmen and self-performs much of the capital work. maintains a 

100,000 square foot shop with custom fabrication capability for pharmaceutical processes 

including a stainless steel welding facility with passivation capability. has been ISO-9000 

certified for 25 years, maintains an outstanding safety record and has a New York State certified 

apprenticeship program for workforce development.

has provided over 140 million dollars in project services to Kodak. Programs and projects 

that has completed for Kodak include:

• Engineering, Design and Construction of MACT Chemical System 

(b) (4)

(b) (4) (b) (4) (b) (4)(b) (4) (b) (4) (b) (4) (b) (4) (b) (4)(b) (4)
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 43 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

• Engineer, Design and Installation of CPDI System

• Kodak Gemini Project Class 1 & 2 Engineering

• Chemical Plant Dual State Filtration System

• Project Management and Installation Kodak Xiamen Plant.

• Acid Plant Design and Construction

• Software Configuration and Upgrade Roll Coating Machine

• Batch Chemical Custom Batch Mix System

• Make and Deliver Systems for Film Coating

• QC Lab Expansion 

Quality Services are Certified Best Practices. Governing corporate processes is a 

Quality Management System registered to ISO 9001 since 1994. In addition to its ISO 

9001:2015 Registration is also registered to the Best Practices of the Control System 

Integrators Association Certification (CSIA). As a founding member of CSIA, is committed 

to improving the business practices of Controls and Information System Integrators. This 

effectively couples the advantages of an ISO 9001 Quality System to the best practices of 

CSIA. The emphasis is on process documentation. The organization has defined quality 

processes for each function of its operation. Quality Policy embodies the fact that 

“Employees of are committed to building lasting client relationships by striving to provide 

consistently superior project services.” — The pursuit of a repeatable and sustainable approach 

to business makes unique as one of only a few firms that are recognized by both ISO 9001 

and CSIA quality systems.

As a control system integrator maintains a full staff of automation engineers and technicians 

trained and certified to use all the major brands of control hardware and software. Expertise 

includes sophisticated batch and continuous control capabilities operating with the best 

functionality of Industry 4.0 technology. supports a panel fabrication facility registered to UL 

standards.

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4)(b) (4) (b) (4) (b) (4)(b) (4)

Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 45 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

the New Business Team Technical Director (or designee) and for internal programs, the 

Customer.

The actual design and development processes utilized by SCID and the results generated are 

documented and controlled. Typically, materials under consideration for commercialization are 

screened using statistical design of experiments methodology. Factors are varied and their 

impact on key physical responses are determined. Modelling identifies the optimal and most 

robust settings for each of the factors. Products are then prepared multiple times at bench, pilot 

and manufacturing scales and the physical attributes of the product are verified. The means of 

each response at each level are analyzed for differences and materials are declared scalable 

when no practical differences are present. Products have limits in place for key quality 

parameters at the time of manufacture which collectively form a specification. The specification 

lists the release characteristics, unit of measures, limits and test method references. Those 

based on fitness-for-use are deemed most desirable but when not, they are based on 

manufacturing capability. Specifications are stored and maintained in an ISO 9001 database. 

12) Quality Systems at Kodak

Specialty Chemicals (SCID) is one of multiple departments that report up to the Eastman Kodak 

Corporation through AMC Advanced Materials and Chemical Division. SCID functions aligned 

with the Mission, Strategic Direction and Business goals set by AMC management. We are ISO 

9001-2015 certified. 

SCID is a customer focused chemical manufacturing organization. Our strategy is to provide a 

broad and profitable portfolio through new innovative ideas as well as utilizing our core 

manufacturing competencies. In supplying a variety of industrial products, SCID works closely 

with its customers making products that meet specified requirements from existing processes or 

commercialized with close customer input through use of a process development gate model 

(KMCP). SCID functions in compliance with all applicable quality, legal, statutory and regulatory 

requirements. The facilities and its employees are managed under all corporate policies, 

Business Practices, guidelines and values. 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 46 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

SCID is based on the following QMS -process model. This model reflects the major processes 

of SCID’s QMS, their interactions, and their alignment with customer focus.

Figure 10. SCID Workflow

Within this Business Model there are a number of internal and external issues relevant to our 

operating plan. SCID has identified the critical components of our business and has put in place 

programs and activities to ensure continuity and reduce impact of change. These issues are 

outlined in the Specialty Chemicals Continuity of Supply Plan

As business conditions change year on year, SCID management participates in a number of 

activities to define our strategies and initiatives along with the associated risks. These issues 

are documented and discussed as part of our annual budgeting and ling term strategic planning 

processes.

13) Workforce Development

The Western New York region includes a strong network of academic institutions, including 

more than 19 colleges and universities and over 81,000 students. According to the U.S. 

Department of Education, Rochester ranks third in both biological and biomedical sciences 

degrees per area among 53 of the largest metro areas. 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 47 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

In addition to prominent institutions such as the University of Rochester and Rochester Institute 

of Technology (RIT), the Greater Rochester area is home to several strong community colleges, 

including Monroe, Genesee and Finger Lakes Community Colleges. These schools offer 

customized programs that support the real-time needs of Upstate New York businesses. 

Local government, community, business and academic leaders have cultivated a strong 

innovation ecosystem that includes a Downtown Innovation Zone, university incubators (e.g. 

URVentures, RIT Venture Creations), and several labs and centers of excellence.

14) Key Personnel

James V. Continenza, Executive Chairman

Jim Continenza leads the transformation of Eastman Kodak Company as Executive Chairman. 

He was appointed to that position by the Board of Directors on February 20, 2019. Continenza 

joined the Board of Directors of Kodak in April 2013 and became Chairman of the Board in 

September 2013.

Continenza brings a proven track record of guiding leading technology companies through 

transformations. Since September 2012, Continenza has served as the Chairman and Chief 

Executive Officer of Vivial, Inc., a privately-held marketing technology and communications 

company. He has also held leadership roles at STi Prepaid, LLC, a telecommunications 

company; Anchor Glass Container Corp., a leading manufacturer of glass containers; Teligent, 

Inc., which provides communications services including voice, data, and internet access; Lucent 

Technologies Product Finance, a global leader in telecom equipment and AT&T.

In addition to his management experience, Mr. Continenza currently serves on the board of 

Cenveo Corporation, an industry leader in transformative publishing solutions. Continenza also 

serves on the board of Merrill Corporation LLC and has served on the boards of NII Holdings, 

Inc., Tembec and Neff Corporation. He also serves or has served on the boards of a number of 

private companies.

Terry R. Taber, PhD, Chief Technical Officer, Senior Vice President, Advanced Materials 

and Chemicals, Vice President, Eastman Kodak Company

Terry Taber joined Kodak in 1980. In January 2009, he was named Chief Technical Officer, a 

position he currently holds. The Board of Directors elected him a corporate vice president in 

December 2008. Effective January 1, 2015, Taber was named President of the newly created 

Intellectual Property Solutions segment. Effective May 1, 2017, Dr. Taber was named President 

of Advanced Materials & 3D Printing Technology Division. Effective March 5, 2020, Taber was 

named Senior Vice President, Advanced Materials and Chemicals, expanding his prior role to 

include oversight of chemicals, functional print and all films, including motion picture, consumer, 

professional and industrial. He reports to Executive Chairman Jim Continenza.

Taber was previously the Chief Operating Officer of Kodak’s Image Sensor Solutions (ISS) 

business, a leading developer of advanced CCD and CMOS sensors serving imaging and 

industrial markets. Prior to joining ISS in 2007, Taber held a series of senior positions in 

Kodak’s research and development and product organizations. During his more than 35 years at 
Establishing a U.S. Center of Excellence for the Production of Key Starting Materials & Active 

Pharmaceutical Ingredients for Essential Medicines 

Page 48 of 48

Eastman Kodak Company – CONFIDENTIAL – COMPETITION SENSITIVE

Use or disclosure of the proposal data are subject to the restrictions in Section 2 of this proposal

Kodak, Taber has been involved in new materials research, product development and 

commercialization, manufacturing, and executive positions in R&D and business management.

Taber’s early responsibilities included research on new synthetic materials, an area in which he 

holds several patents. He then became a program manager for several film products before 

completing the Sloan Fellows program at the Massachusetts Institute of Technology (MIT). He 

returned from MIT to become the worldwide consumer film business product manager from 

1999 to 2002, and then became an Associate Director of R&D from 2002 to 2005, followed by a 

position as the director of Materials & Media R&D from 2005 to 2007.

Taber received a B.S. degree in Chemistry from Purdue University and a Ph.D. in Organic 

Chemistry from the California Institute of Technology. He also received an M.S. in General 

Management from MIT as a Kodak Sloan Fellow. Taber was a Board Member of the Innovation 

& Material Sciences Institute and currently serves on the Executive Advisory Board of FIRST 

Rochester (For Inspiration and Recognition of Science and Technology). He also serves on the 

Executive Committee of the Greater Rochester Chamber of Commerce and the Tocqueville 

Society Cabinet of the Greater Rochester United Way. Taber is a trustee of Roberts Wesleyan 

College and Northeastern Seminary.

15) Organizational Chart- Kodak Pharma

Figure 1: Project Organizational Chart

Board 

Continenza, Moran, 

Goldbarg, Bullwinkle, 

Byrd, Taber

CEO Continenza

Outsourced

Audit and Tax

Corp Counsel

Public Relations

Finance

Dir. Finance

Dir. Controller

Mgr. Compliance

Sales & Marketing

Dir. Sales

Dir. Marketing

Dir. Gov't Relations

Dir. Communications

Legal/Gov Affairs

VP Legal

Dir. Regulatory 

Affairs

Dir. Gov't Affairs

Mgr. Proposals and 

Document Mgt

Corporate 

Operations

Dir. Corp 

Development

Dir. Strategic 

Reserve

Dir. Capital Projects

Dir. IT/Data Security

Dir. HR

Dir. Procurement

Mgr. Office Admin

Technology & 

Innovation

CTO Research & 

Development

Center of Excellence 

for Pharma 

Mgr. Health, Safty 

and Environment

Dir. Quality

Manufacturing & 

Operations

Dir. Manufacturing

Dir. Plant Operations

Dir. Supply Chain

From: Penna, David

To: Abbott, Christopher J. EOP/WHO; Continenza, James V; "Taber, Terry [Terry] R"; "

"

Cc: Glaccum, David (FO); Ackerly, Stewart; Smith, Austin

Subject: RE: Kodak Project

Date: Monday, June 1, 2020 3:57:19 PM

Attachments: Potential KODK Starting Materials and API Structure 6.1.20.pptx

Hi all, great to meet everyone this morning. Further to our conversation, attached please find a very

preliminary structure diagram showing how a non-recourse financing might work based on what we

know about the project at this time. Please note that this slide is for discussion purposes only, in

hopes that it helps people start organizing thoughts on how the pieces might fit together in terms of

financing structure for this sort of thing, while trying to minimize additional costs/friction with the

existing business.

Again, this is just a rough first draft, but happy to discuss further.

Thanks,

DJP

David J. Penna

Senior Vice President, Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Ave, NW | Washington DC 20527

| | www.dfc.gov

From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < 'Taber, Terry [Terry] R'

< ' <

' <

Cc: Glaccum, David (FO) < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

 on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

B001

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4) (b) (4)
Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6)


We very much appreciate your rapid response and will be working through this in parallel with our

more detailed proposal.

Regards,

Dave Bullwinkle

From: Penna, David <

Sent: Monday, June 1, 2020 3:57 PM

To: Abbott, Christopher J. EOP/WHO < Continenza, James V

< Taber, Terry [Terry] R < Bullwinkle, David E

< Byrd, Roger W <

<

Cc: Glaccum, David (FO) < Ackerly, Stewart <

Smith, Austin <

Subject: RE: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Hi all, great to meet everyone this morning. Further to our conversation, attached please find a very

preliminary structure diagram showing how a non-recourse financing might work based on what we

know about the project at this time. Please note that this slide is for discussion purposes only, in

hopes that it helps people start organizing thoughts on how the pieces might fit together in terms of

financing structure for this sort of thing, while trying to minimize additional costs/friction with the

existing business.

Again, this is just a rough first draft, but happy to discuss further.

Thanks,

DJP

David J. Penna

Senior Vice President, Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Ave, NW | Washington DC 20527

| | www.dfc.gov

From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < 'Taber, Terry [Terry] R'

< <

 <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)
Cc: Glaccum, David (FO) < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4)



Cc: Glaccum, David (FO) < Ackerly, Stewart <

Smith, Austin <

Subject: RE: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Hi all, great to meet everyone this morning. Further to our conversation, attached please find a very

preliminary structure diagram showing how a non-recourse financing might work based on what we

know about the project at this time. Please note that this slide is for discussion purposes only, in

hopes that it helps people start organizing thoughts on how the pieces might fit together in terms of

financing structure for this sort of thing, while trying to minimize additional costs/friction with the

existing business.

Again, this is just a rough first draft, but happy to discuss further.

Thanks,

DJP

David J. Penna

Senior Vice President, Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Ave, NW | Washington DC 20527

| | www.dfc.gov

From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < 'Taber, Terry [Terry] R'

< <

 < <

Cc: Glaccum, David (FO) < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

 on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)
Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6)
From: Taber, Terry [Terry] R

To: Glaccum, David (FO); Penna, David; Smith, Austin; Ackerly, Stewart

Cc: Continenza, James V; Abbott, Christopher J. EOP/WHO

Subject: RE: Kodak Project

Date: Wednesday, June 3, 2020 8:48:15 PM

Attachments: image001.png

Eastman Kodak Company.Technical Proposal.June 3.pdf

Eastman Kodak Company.Proposal Schedule.June 3.pdf

Eastman Kodak Company.Cost Proposal.June 3.pdf

Eastman Kodak Company.Eastman Business Park Attributes.June 3.pdf

*** Careful. This email originated from a non-government source. When in doubt, please reach out:

ciso@dfc.gov ***

DFC group,

Per Chris’ request, I am sending along the latest Kodak documents:

1. Technical Proposal – this is the comprehensive overview to establish

a U.S. Center of Excellence for the Production of Key Starting

Materials & Active Pharmaceutical Ingredients for Essential

Medicines

2. A Proposal Schedule that outlines the spend profile by CLIN and by

time period for the technical proposal

3. Overall Cost Proposal associated with this proposed project

4. A brochure on the attributes of Eastman Business Park

We look forward to continuing our dialogue.

Best,

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

B004

(b) (6) (b) (6) (b) (6)
From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < Taber, Terry [Terry] R

< Bullwinkle, David E < Byrd, Roger W

< <

Cc: 'Glaccum, David (FO)' < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)


From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < Taber, Terry [Terry] R

< Bullwinkle, David E < Byrd, Roger W

< <

Cc: 'Glaccum, David (FO)' < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

 on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)


From: Glaccum, David (FO) <

Sent: Thursday, June 4, 2020 5:48 PM

To: Taber, Terry [Terry] R; Penna, David; Smith, Austin; Ackerly, Stewart

Cc: Continenza, James V; Abbott, Christopher J. EOP/WHO

Subject: RE: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Terry,

Thanks again for sending over. Do y’all have time for a follow-up call tomorrow afternoon?

DMG

From: Glaccum, David (FO) <

Sent: Wednesday, June 3, 2020 9:01 PM

To: Taber, Terry [Terry] R < Penna, David < Smith,

Austin < Ackerly, Stewart <

Cc: Continenza, James V < Abbott, Christopher J. EOP/WHO

<

Subject: Re: Kodak Project

Thanks, Terry. We’ll take a look and he in touch tomorrow.

From: Taber, Terry [Terry] R <

Sent: Wednesday, June 3, 2020 8:47:09 PM

To: Glaccum, David (FO) < Penna, David < Smith,

Austin < Ackerly, Stewart <

Cc: Continenza, James V < Abbott, Christopher J. EOP/WHO

<

Subject: RE: Kodak Project

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < Taber, Terry [Terry] R

< Bullwinkle, David E < Byrd, Roger W

< <

Cc: 'Glaccum, David (FO)' < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)




Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Abbott, Christopher J. EOP/WHO <

Sent: Monday, June 1, 2020 11:41 AM

To: Continenza, James V < Taber, Terry [Terry] R

< Bullwinkle, David E < Byrd, Roger W

< <

Cc: 'Glaccum, David (FO)' < Ackerly, Stewart <

Penna, David < Smith, Austin <

Subject: Kodak Project

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

All,

Thanks for the call this morning. As discussed, I am connecting everyone from DFC, Kodak, and

on this email chain.

Jim, can you have your team send over all of the latest documents you have to keep things moving

on this?

Thanks,

Chris

Christopher Abbott

Deputy Director

Office of Trade and Manufacturing Policy

The White House

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)

From: Taber, Terry [Terry] R

To: Glaccum, David (FO)

Cc: Penna, David; Ackerly, Stewart; Smith, Austin; Abbott, Christopher J. EOP/WHO; Bullwinkle, David E; Continenza,

James V; Byrd, Roger W

Subject: RE: DFC/DPA web page and application

Date: Saturday, June 6, 2020 9:25:42 AM

Attachments: image001.png

Updated Table 1 from EKC Technical Proposal 2020Jun5.pdf

Eastman Kodak Company Summary of Kodak Schedule 2020Jun5.pdf

Eastman Kodak Company Cost Proposal 2020Jun5.pdf

*** Careful. This email originated from a non-government source. When in doubt, please reach out:

 ***

Thank you, David.

As noted on our call Friday, attached are the updated cost estimates.

Best,

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Glaccum, David (FO) <

Sent: Friday, June 5, 2020 4:28 PM

To: Byrd, Roger W < Continenza, James V <

Taber, Terry [Terry] R < Overacker, Maryann R

< Bullwinkle, David E <

Cc: Penna, David < Ackerly, Stewart < Smith,

Austin < Abbott, Christopher J. EOP/WHO

<

Subject: DFC/DPA web page and application

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

B008

Attachments duplicative with prior FOIA records release; A0003; A0004; A0007.

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
and content are safe.

Team Kodak,

Great talking with y’all again today. Per our conversation, the website and application are now

available here: https://www.dfc.gov/dpa. You can apply here: https://www.dfc.gov/what-weoffer/apply

Please let us know if you have any questions as you review, and we look forward to taking the next

steps on this project.

DMG

David M. Glaccum

Counsel to the Chief Executive

U.S. International Development Finance Corporation



Subject: DFC/DPA web page and application

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Team Kodak,

Great talking with y’all again today. Per our conversation, the website and application are now

available here: https://www.dfc.gov/dpa. You can apply here: https://www.dfc.gov/what-weoffer/apply

Please let us know if you have any questions as you review, and we look forward to taking the next

steps on this project.

DMG

David M. Glaccum

Counsel to the Chief Executive

U.S. International Development Finance Corporation

Sent: Thursday, June 11, 2020 6:02:56 PM

To: Taber, Terry [Terry] R <

Cc: Penna, David < Ackerly, Stewart < Smith, Austin

< Abbott, Christopher J. EOP/WHO <

Bullwinkle, David E < Continenza, James V

< Byrd, Roger W <

<

Subject: Re: DFC/DPA web page and application

Team Kodak,

Hope all is well.

Wanted to see if y’all wanted to touch base tomorrow and discuss where things stand.

Thanks.

DMG

From: Glaccum, David (FO) <

Sent: Saturday, June 6, 2020 10:13:40 AM

To: Taber, Terry [Terry] R <

Cc: Penna, David < Ackerly, Stewart < Smith, Austin

< Abbott, Christopher J. EOP/WHO <

Bullwinkle, David E < Continenza, James V

< Byrd, Roger W <

Subject: Re: DFC/DPA web page and application

Thank you.

From: Taber, Terry [Terry] R <

Sent: Saturday, June 6, 2020 9:25:11 AM

To: Glaccum, David (FO) <

Cc: Penna, David < Ackerly, Stewart < Smith, Austin

< Abbott, Christopher J. EOP/WHO <

Bullwinkle, David E < Continenza, James V

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)

Team Kodak,

Great talking with y’all again today. Per our conversation, the website and application are now

available here: https://www.dfc.gov/dpa. You can apply here: https://www.dfc.gov/what-weoffer/apply

Please let us know if you have any questions as you review, and we look forward to taking the next

steps on this project.

DMG

David M. Glaccum

Counsel to the Chief Executive

U.S. International Development Finance Corporation

For a sampling of the coverage, please see the links below.

This excerpt from one story captures the consensus about our new direction: “Kodak is making

good on its promise to create new opportunities for growth. By doubling down on digital and inkjet,

Kodak is well-positioned to capture the opportunities with the accelerated shift to digital print that

the world is now experiencing. With Executive Chairman Jim Continenza reshaping the company’s

structure and molding a new organization, we can expect a very aggressive Kodak to emerge in our

changing digital print world.”

Thank you all 100% for everything you are doing for the country.

We are Look forward to building an alliance together for all of America.

Thank you,

Jim

Printweek UK

Australian Printer and Pro Print

Printing Impressions

Keypoint Intelligence

Packaging South Asia

Jim Continenza | Executive Chairman | Eastman Kodak Company 

343 State Street Rochester, NY 14650-0231 

www.kodak.com

(b) (6)

FDA Drug Shortages Task Force. (2019). Drug Shortages: Root Causes and Potential Solutions.

Retrieved from https://www.fda.gov/media/131130/download.

Paula Kim, MBA PMP

Sr. Director

(b) (4), (b) (6)
From: Allal, Alale

To: Continenza, James V

Cc: Allal, Alale

Subject: RE: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

Date: Thursday, July 9, 2020 1:58:18 PM

Attachments: image003.png

Eastman Kodak Financial Projections_2019 06_25_2020 V2 Final.xlsm

Hi Jim,

Thank you for providing. Can you please have the appropriate person update the attached Financial Projections to reflect the new expenses including the interest expense

assuming an interest rate of and send back to me at your earliest?

I’m working on your term sheet and wanted to get an idea of timeline for establishing a name for the SPV? We typically include that in our term sheets to borrowers.

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

ministration

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Continenza, James V 

Sent: Wednesday, July 8, 2020 5:53 PM

To: Allal, Alale Continenza, James V 

Subject: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

CAUTION - The sender of this message is external to the SBA network. Please use care when clicking on links and responding with sensitive information. Send

suspicious email to spam@sba.gov.

Allal,

Attached are 3 financial models we discussed for the various loan terms. Also attached is a summary (see pdf file) which shows the loan terms assumptions, timing of cash

disbursements, as well and SVP projected ending cash balance for the short-term (annually) and long-term (every 5 years).

Thank you,

Regards,

Jim

(b) (4)

(b) (4)

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)

(b) (6)

(b) (6) (b) (6) (b) (6)
From: Continenza, James V

To: Allal, Alale; Continenza, James V

Cc: Allal, Alale

Subject: Re: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

Date: Thursday, July 9, 2020 5:42:07 PM

Attachments: image002.png

Eastman Kodak Financial Projections_2019 06_25_2020 ($765M@5.0%)[3].xlsm

Warning: External

Allal, Please find attached the updated Financial Projections to reflect the new expenses including the interest expense assuming an interest rate of

We are in the process of reserving the name this week, we will slow roll the entities formation to protect confidentially because we are a public company.

Regards,

Jim

From: "Allal, Alale" <

Date: Thursday, July 9, 2020 at 1:55 PM

To: "Continenza, James V" <

Cc: " <

Subject: RE: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender and content are safe.

Hi Jim,

Thank you for providing. Can you please have the appropriate person update the attached Financial Projections to reflect the new expenses including the interest expense

assuming an interest rate of and send back to me at your earliest?

I’m working on your term sheet and wanted to get an idea of timeline for establishing a name for the SPV? We typically include that in our term sheets to borrowers.

Timeline this Friday

Name: Kodak Pharmaceuticals, INC.

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Continenza, James V <

Sent: Wednesday, July 8, 2020 5:53 PM

To: Allal, Alale < Continenza, James V <

Subject: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

CAUTION - The sender of this message is external to the SBA network. Please use care when clicking on links and responding with sensitive information. Send

suspicious email to 

Allal,

Attached are 3 financial models we discussed for the various loan terms. Also attached is a summary (see pdf file) which shows the loan terms assumptions, timing of cash

disbursements, as well and SVP projected ending cash balance for the short-term (annually) and long-term (every 5 years).

Thank you,

Regards,

Jim

B014

(b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)
(b) (4)

(b) (4)

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
From: Allal, Alale

To: Continenza, James V; Taber, Terry [Terry] R

Cc: Allal, Alale

Subject: Questions

Date: Friday, July 10, 2020 5:15:17 PM

Attachments: 20200710.v2_Kodak_Memo_Technical_Questions.docx

Jim,

Attached, please find our first set of question from DOD that will need to be answered. I do have

some additional follow-up questions that are coming from HHS that will be sent your way early next

week. Would you and the Kodak team be available to discuss the initial Term Sheet on Monday?

 One of the key areas that we need to address is the 60 day definitive agreement with per

your LOI that was recently executed?

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

B015

(b) (6) (b) (6) (b) (4)
From: Allal, Alale

To: Continenza, James V

Cc: Allal, Alale

Subject: RE: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

Date: Monday, July 13, 2020 8:10:54 AM

Attachments: image005.png

Good morning Jim,

We will be booking travel this week for the site visit and to meet with you and the team on 07/22 at 2pm. Can you please have your assistant reach out to me regarding

logistics? I’m still waiting on confirmation for who all will be traveling with me, but will have those names to you later this week.

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Continenza, James V <

Sent: Thursday, July 9, 2020 4:40 PM

To: Allal, Alale < Continenza, James V <

Cc:

Subject: Re: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

CAUTION - The sender of this message is external to the SBA network. Please use care when clicking on links and responding with sensitive information. Send

suspicious email to 

Allal, Please find attached the updated Financial Projections to reflect the new expenses including the interest expense assuming an interest rate of 

We are in the process of reserving the name this week, we will slow roll the entities formation to protect confidentially because we are a public company.

Regards,

Jim

From: "Allal, Alale" <

Date: Thursday, July 9, 2020 at 1:55 PM

To: "Continenza, James V" <

Cc: " <

Subject: RE: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender and content are safe.

Hi Jim,

Thank you for providing. Can you please have the appropriate person update the attached Financial Projections to reflect the new expenses including the interest expense

assuming an interest rate of and send back to me at your earliest?

I’m working on your term sheet and wanted to get an idea of timeline for establishing a name for the SPV? We typically include that in our term sheets to borrowers.

Timeline this Friday

Name: Kodak Pharmaceuticals, INC.

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

B016

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4)
Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Continenza, James V <

Sent: Wednesday, July 8, 2020 5:53 PM

To: Allal, Alale < Continenza, James V <

Subject: Eastman Kodak SPV Loan Scenario Summary and 3 Scenario Models

CAUTION - The sender of this message is external to the SBA network. Please use care when clicking on links and responding with sensitive information. Send

suspicious email to spam@sba.gov.

Allal,

Attached are 3 financial models we discussed for the various loan terms. Also attached is a summary (see pdf file) which shows the loan terms assumptions, timing of cash

disbursements, as well and SVP projected ending cash balance for the short-term (annually) and long-term (every 5 years).

Thank you,

Regards,

Jim

(b) (6) (b) (6) (b) (6)

(b) (4)

(b) (4) (b) (4)(b) (4) (b) (4) (b) (4) (b) (4)
From: Overacker, Maryann R

To: Allal, Alale; Allal, Alale

Subject: RE: Rochester Visit - July 22

Date: Wednesday, July 15, 2020 6:37:54 PM

Attachments: image001.png

Warning: External

Hi Alale, the meeting would most likely start at Kodak Office, 343 State Street, Rochester, NY 14650.

From there you would go down to Eastman Business Park. I will discuss the agenda with Jim and get

back to you.

Maryann Overacker | Executive Assistant to Jim Continenza, Executive Chairman | Eastman Kodak Company 

 Office: Cell:

www.kodak.com

From: Allal, Alale <

Sent: Wednesday, July 15, 2020 6:16 PM

To: Overacker, Maryann R <

Cc: Overacker, Maryann R <

Subject: Re: Rochester Visit - July 22

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Hi Maryann,

Can you provide me with the physical address to where we would meet and a tentative

agenda?

Best regards,

Alale Allal

Export Finance Director

Office of International Trade

U.S. Small Business Administration

B017

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Overacker, Maryann R <

Sent: Monday, July 13, 2020 10:56:11 AM

To: Allal, Alale < <

Cc: Overacker, Maryann R <

Subject: RE: Rochester Visit - July 22

CAUTION - The sender of this message is external to the SBA network. Please use care when

clicking on links and responding with sensitive information. Send suspicious email to

Alale, see below for responses:

Best airport to fly into?

Greater Rochester International Airport (ROC) - 1200 Brooks Avenue, Rochester, NY 14624

3 Best hotels to consider staying at while in Rochester?

I would recommend either of the below hotels:

The Del Monte Lodge Renaissance Rochester Hotel & Spa, 41 N. Main Street, Pittsford,

NY 14534 (Phone 

The Strathallan Rochester Hotel & Spa - a DoubleTree by Hilton, 550 East Ave,

Rochester, NY 14607 (Phone: 

Because we are with the U.S. Government, we will rely on public transportation (Uber, Lift,

etc.) for transportation from the airport to the hotel. We will probably need help with

transportation from the Hotel to the meeting location on 07/22 at 2pm and transportation back

to the airport once the meeting concludes. Can you assist with that?

Yes, I would be happy to provide transportation from hotel to meeting location and then

back to the airport.

As for transportation from the airport to hotel upon arrival, if we cannot assist, I would

recommend a private service if that is an option for you or taxi service from the airport.

Uber and Lyft is not always readily available. The private service I would recommend is:

Shuffles Limousine Service, 1060 Lyell Avenue, Rochester, NY 14606. Ph 

or 

Maryann Overacker | Executive Assistant to Jim Continenza, Executive Chairman | Eastman Kodak Company 

 Office: Cell:

www.kodak.com

From: Allal, Alale <

Sent: Monday, July 13, 2020 11:31 AM

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
To: Overacker, Maryann R <

Subject: RE: Rochester Visit - July 22

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Good morning Maryann,

Please provide me with the following and I should be able to circle back on your questions below:

Best airport to fly into?

3 Best hotels to consider staying at while in Rochester?

Because we are with the U.S. Government, we will rely on public transportation (Uber, Lift,

etc.) for transportation from the airport to the hotel. We will probably need help with

transportation from the Hotel to the meeting location on 07/22 at 2pm and transportation back

to the airport once the meeting concludes. Can you assist with that?

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Overacker, Maryann R <

Sent: Monday, July 13, 2020 9:08 AM

To: Allal, Alale <

Cc: Overacker, Maryann R <

Subject: Rochester Visit - July 22

CAUTION - The sender of this message is external to the SBA network. Please use care when

clicking on links and responding with sensitive information. Send suspicious email to

Hi Alale, I am Jim Continenza’s executive assistant and Jim informed me that you will be coming to

Rochester next Wednesday, July 22 for a 2 pm site visit and meeting.

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
I will be helping with logistics for your visit. Please let me know your plans for your trip when you

can:

Flight details

Participants

Will you be needing a hotel? 

We will take care of all ground transportation arrangements

Any other special considerations

Thank you.

Maryann Overacker

Maryann Overacker | Executive Assistant to Jim Continenza, Executive Chairman | Eastman Kodak Company 

 Office: Cell:

www.kodak.com

(b) (6) (b) (6) (b) (6)
From: Allal, Alale

To: Continenza, James V; Taber, Terry [Terry] R; Gutkin, Paula J

Cc: Allal, Alale

Subject: Follow-up questions

Date: Sunday, July 19, 2020 11:29:05 AM

Attachments: 07-19-2020.v3_Kodak_Memo_Technical_Questions (002).docx

Good morning Jim and Kodak Team:

Please note attached follow-up questions from DoD and HHS that I will need answered before

Tuesday, 07-21-2020 if possible. I know the detailed marketing plan will require some work, but it’s

also needed and it would/should address one of the questions raised by HHS.

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

B018

(b) (6) (b) (6)
From: Allal, Alale

To: Continenza, James V

Cc: Allal, Alale

Subject: Term Sheet

Date: Thursday, July 23, 2020 8:05:44 PM

Attachments: Kodak Pharmaceuticals, Inc. - DFC PF Term Sheet for DPA Loan (Legal Comments 7.23.2020) - CLEAN.docx

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

B019

(b) (6) (b) (6)
From: Goldbarg, Denisse

To: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: Re: Update on Planning for DFC/Kodak Event

Date: Saturday, July 25, 2020 7:03:33 AM

Attachments: Kodak pharma announcement talk points JC quote FINAL.docx

Kodak_Center_Theater_Photos_and_Floor_Plan.zip

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal specific

requirements please let us know

B020

(b) (6) (b) (6)
From: Bell, Olivia (OEA)

To: Goldbarg, Denisse; Burke, Amanda (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel,

Rachael (FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: RE: Update on Planning for DFC/Kodak Event

Date: Saturday, July 25, 2020 10:48:46 AM

Attachments: Event Media Advisory_Kodak_7.24.20.docx

Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued support.

Please find a draft media advisory attached (with placeholders for a couple logistical items that

Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

B021

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal specific

requirements please let us know
From: Goldbarg, Denisse

To: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: Run of Show

Date: Saturday, July 25, 2020 10:54:07 AM

Attachments: Run of Show 072820 DFC-Kodak v1.doc

Warning: External

All: Attached and copied below is a first draft of the complete run of show. I have

highlighted in yellow those items that are still open. Key open items are arrival time for

the tour and number of guests. Please let us know your thoughts. 

Kodak Facilities Tour

Starts at Kodak Center: 200 W Ridge Rd, Rochester, NY 14615

Date: June 28, 2020 at XX:00

Flow of Tour for Tuesday, July 28

0:00 --- Leave Kodak Center (address above) on bus (es); discuss aspects of Eastman Business

Park along the trip to Syn Chem

0:10 --- Arrive Eastman Business Park West, assemble inside, and put on safety gear

(hard hats, safety glasses, lab coats): Note: cell phones and other electronic devices must be

turned off or left at secure location

0:15 --- Begin tour of chemical mfg site with focus on which will become part of the

pharma SPV

0:35 --- Return to CR and leave safety gear; retrieve phones

0:40 --- Leave for Kodak Research Labs; more discussion on aspects of Eastman Business

Park

0:48 --- Arrive Kodak Research Labs; begin tour with focus on labs/space for Center of

Excellence, test reagents and the Analytical labs and capability.

1:05 --- return to bus, depart for Kodak Center

1:15 --- arrive at Kodak Center

1:20 --- assemble inside theater

Government Participants: 8+ - TBD

Kodak Participants:

B022

(b) (6) (b) (6) (b) (4) (b) (4) (b) (4)
On Bus: Terry Taber, Jim Continenza

At Nagraj Bokinkere

At KRL: Kevin Williams

Kodak-DFC Signing Ceremony

Signing Event Scenario

Location: Kodak Center

200 W Ridge Rd, Rochester, NY 14615

Speakers: Adam Boehler, Chief Executive Officer, U.S. International Development

Finance Corporation

Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Denisse Goldbarg Chief Marketing Officer, Kodak (Moderator)

Signing: Adam Boehler, CEO, U.S. International Development Finance Corporation

Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Attendees: TBD

Press

00:00 Goldbarg gives welcoming remarks and introduces Boehler and Continenza 

00:01 Boehler and Continenza take seats at signing table 

00:02 Boehler and Continenza sign official documents 

00:03 Signatories shake hands with one another while seated then stand (Photo-op)

00:04 Goldbarg invites Continenza to the podium 

00:05 Continenza makes brief remarks

00:10 Goldbarg invites Boehler to the podium 

00:11 Boehler makes brief remarks

00:16 Boehler introduces live video message from President Trump

00:17 President Trump delivers remarks

00:22 Goldbarg opens the event up to questions from reporters

00:32 Boehler and Continenza respond to questions

00:33 Goldbarg closes the event

00:35 Ceremony conclude 

(b) (4)
From: Bell, Olivia (OEA)

To: Goldbarg, Denisse; Burke, Amanda (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel,

Rachael (FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: RE: Update on Planning for DFC/Kodak Event

Date: Saturday, July 25, 2020 10:56:58 AM

Makes sense. We defer to you on those logistical details.

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 10:55 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Olivia I will review in detail but one item to note is the event is taking place at the Kodak

Center. On the run of show I just shared the address is there. Think it makes sense to use that

address unless anyone objects.

dg

From: Bell, Olivia (OEA) <

Sent: Saturday, July 25, 2020 10:48 AM

To: Goldbarg, Denisse < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen, Laura (OEA)

< Bulgrin, Julie < Baitel, Rachael (FO)

< Continenza, James V < Horstman, John H.

EOP/WHO < Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO <

 < Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< <

Glaccum, David (FO) < Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: RE: Update on Planning for DFC/Kodak Event

B023

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued support.

Please find a draft media advisory attached (with placeholders for a couple logistical items that

Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal specific

requirements please let us know

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Burke, Amanda (OEA)

To: Goldbarg, Denisse; Bell, Olivia (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: RE: Run of Show

Date: Saturday, July 25, 2020 1:07:31 PM

Attachments: Run of Show 072820 DFC-Kodak 07252020 1pm version.doc

Thanks, Denisse. I made a few updates on the ceremony portion. Looking at the arrival time and the

ceremony start time, we may need to trim back the factory tour to 45 mins. Is that possible?

Thanks,

Amanda

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 10:52 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Run of Show

Warning: External

All: Attached and copied below is a first draft of the complete run of show. I have

highlighted in yellow those items that are still open. Key open items are arrival time for

the tour and number of guests. Please let us know your thoughts. 

Kodak Facilities Tour

B024

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Starts at Kodak Center: 200 W Ridge Rd, Rochester, NY 14615

Date: June 28, 2020 at XX:00

Flow of Tour for Tuesday, July 28

0:00 --- Leave Kodak Center (address above) on bus (es); discuss aspects of Eastman Business

Park along the trip to Syn Chem

0:10 --- Arrive , Eastman Business Park West, assemble inside, and put on safety gear

(hard hats, safety glasses, lab coats): Note: cell phones and other electronic devices must be

turned off or left at secure location

0:15 --- Begin tour of chemical mfg site with focus on which will become part of the

pharma SPV

0:35 --- Return to CR and leave safety gear; retrieve phones

0:40 --- Leave for Kodak Research Labs; more discussion on aspects of Eastman Business

Park

0:48 --- Arrive Kodak Research Labs; begin tour with focus on labs/space for Center of

Excellence, test reagents and the Analytical labs and capability.

1:05 --- return to bus, depart for Kodak Center

1:15 --- arrive at Kodak Center

1:20 --- assemble inside theater

Government Participants: 8+ - TBD

Kodak Participants:

On Bus: Terry Taber, Jim Continenza

At : Nagraj Bokinkere

At KRL: Kevin Williams

Kodak-DFC Signing Ceremony

Signing Event Scenario

Location: Kodak Center

200 W Ridge Rd, Rochester, NY 14615

Speakers: Adam Boehler, Chief Executive Officer, U.S. International Development

Finance Corporation

Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Denisse Goldbarg Chief Marketing Officer, Kodak (Moderator)

Signing: Adam Boehler, CEO, U.S. International Development Finance Corporation

(b) (4) (b) (4) (b) (4) (b) (4)
Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Attendees: TBD

Press

00:00 Goldbarg gives welcoming remarks and introduces Boehler and Continenza 

00:01 Boehler and Continenza take seats at signing table 

00:02 Boehler and Continenza sign official documents 

00:03 Signatories shake hands with one another while seated then stand (Photo-op)

00:04 Goldbarg invites Continenza to the podium 

00:05 Continenza makes brief remarks

00:10 Goldbarg invites Boehler to the podium 

00:11 Boehler makes brief remarks

00:16 Boehler introduces live video message from President Trump

00:17 President Trump delivers remarks

00:22 Goldbarg opens the event up to questions from reporters

00:32 Boehler and Continenza respond to questions

00:33 Goldbarg closes the event

00:35 Ceremony conclude 
From: Goldbarg, Denisse

To: Burke, Amanda (OEA); Bell, Olivia (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: Re: Run of Show

Date: Saturday, July 25, 2020 1:28:33 PM

I will go back and ask the team. dg

From: Burke, Amanda (OEA) <

Sent: Saturday, July 25, 2020 1:07 PM

To: Goldbarg, Denisse < Bell, Olivia (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

<

< Morgenstern, Brian R. EOP/WHO

< Benedict, Samantha <

 < Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: RE: Run of Show

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Thanks, Denisse. I made a few updates on the ceremony portion. Looking at the arrival time and the

ceremony start time, we may need to trim back the factory tour to 45 mins. Is that possible?

Thanks,

Amanda

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 10:52 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

B025

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Run of Show

Warning: External

All: Attached and copied below is a first draft of the complete run of show. I have

highlighted in yellow those items that are still open. Key open items are arrival time for

the tour and number of guests. Please let us know your thoughts. 

Kodak Facilities Tour

Starts at Kodak Center: 200 W Ridge Rd, Rochester, NY 14615

Date: June 28, 2020 at XX:00

Flow of Tour for Tuesday, July 28

0:00 --- Leave Kodak Center (address above) on bus (es); discuss aspects of Eastman Business

Park along the trip to Syn Chem

0:10 --- Arrive , Eastman Business Park West, assemble inside, and put on safety gear

(hard hats, safety glasses, lab coats): Note: cell phones and other electronic devices must be

turned off or left at secure location

0:15 --- Begin tour of chemical mfg site with focus on which will become part of the

pharma SPV

0:35 --- Return to CR and leave safety gear; retrieve phones

0:40 --- Leave for Kodak Research Labs; more discussion on aspects of Eastman Business

Park

0:48 --- Arrive Kodak Research Labs; begin tour with focus on labs/space for Center of

Excellence, test reagents and the Analytical labs and capability.

1:05 --- return to bus, depart for Kodak Center

1:15 --- arrive at Kodak Center

1:20 --- assemble inside theater

Government Participants: 8+ - TBD

Kodak Participants:

On Bus: Terry Taber, Jim Continenza

At : Nagraj Bokinkere

At KRL: Kevin Williams

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4) (b) (4) (b) (4)
Kodak-DFC Signing Ceremony

Signing Event Scenario

Location: Kodak Center

200 W Ridge Rd, Rochester, NY 14615

Speakers: Adam Boehler, Chief Executive Officer, U.S. International Development

Finance Corporation

Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Denisse Goldbarg Chief Marketing Officer, Kodak (Moderator)

Signing: Adam Boehler, CEO, U.S. International Development Finance Corporation

Jim Continenza, Executive Chairman and Chief Executive Officer, Kodak

Attendees: TBD

Press

00:00 Goldbarg gives welcoming remarks and introduces Boehler and Continenza 

00:01 Boehler and Continenza take seats at signing table 

00:02 Boehler and Continenza sign official documents 

00:03 Signatories shake hands with one another while seated then stand (Photo-op)

00:04 Goldbarg invites Continenza to the podium 

00:05 Continenza makes brief remarks

00:10 Goldbarg invites Boehler to the podium 

00:11 Boehler makes brief remarks

00:16 Boehler introduces live video message from President Trump

00:17 President Trump delivers remarks

00:22 Goldbarg opens the event up to questions from reporters

00:32 Boehler and Continenza respond to questions

00:33 Goldbarg closes the event

00:35 Ceremony conclude 
From: Goldbarg, Denisse

To: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Allen, Laura (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: Re: Update on Planning for DFC/Kodak Event

Date: Sunday, July 26, 2020 10:15:35 AM

Any update on the timing of receiving the press release? dg

From: Bell, Olivia (OEA) <

Sent: Saturday, July 25, 2020 10:48 AM

To: Goldbarg, Denisse < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen, Laura (OEA)

< Bulgrin, Julie < Baitel, Rachael (FO)

< Continenza, James V < Horstman, John H.

EOP/WHO < Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO <

 < Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< <

Glaccum, David (FO) < Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: RE: Update on Planning for DFC/Kodak Event

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued support.

Please find a draft media advisory attached (with placeholders for a couple logistical items that

Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

B026

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal specific

requirements please let us know

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Allen, Laura (OEA)

To: Goldbarg, Denisse; Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Bulgrin, Julie; Baitel, Rachael

(FO); Continenza, James V; Horstman, John H. EOP/WHO; Farah, Alyssa A. EOP/WHO; Daravi, Roma S.

EOP/WHO; Morgenstern, Brian R. EOP/WHO; Benedict, Samantha;

Glaccum, David (FO); Allal, Alale; 

Cc: Jaeckel, Kurt; Ramplin, Meagan R

Subject: Final media advisory-- 11am tomorrow

Date: Sunday, July 26, 2020 7:33:52 PM

Attachments: Event Media Advisory_Kodak_7.26.2020 v6.docx

All- flagging the final media advisory. Please see attached (and note that Governor Cuomo’s staff

prefers to advise his participation to the press on Tuesday so he is not included in this advisory).

Denisse will send out the advisory at 11am tomorrow morning; DFC will then share it with our press

list.

Let us know if you have any questions before tomorrow.

Many thanks,

Laura Allen

Press Secretary

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, D.C. 20527

m. + |

From: Goldbarg, Denisse <

Sent: Sunday, July 26, 2020 10:15 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Any update on the timing of receiving the press release? dg

From: Bell, Olivia (OEA) <

Sent: Saturday, July 25, 2020 10:48 AM

To: Goldbarg, Denisse < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen, Laura (OEA)

B027

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
< Bulgrin, Julie < Baitel, Rachael (FO)

< Continenza, James V < Horstman, John H.

EOP/WHO < Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO <

 < Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< <

Glaccum, David (FO) < Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: RE: Update on Planning for DFC/Kodak Event

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued support.

Please find a draft media advisory attached (with placeholders for a couple logistical items that

Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Allen, Laura (OEA) < Bulgrin,

Julie < Baitel, Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO <

Farah, Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cc: Jaeckel, Kurt < Ramplin, Meagan R <

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal specific

requirements please let us know

(b) (6) (b) (6)
From: Goldbarg, Denisse

To: Horstman, John H. EOP/WHO; Allen, Laura (OEA)

Cc: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Bulgrin, Julie; Baitel, Rachael (FO); Continenza,

James V; Farah, Alyssa A. EOP/WHO; Daravi, Roma S. EOP/WHO; 

Morgenstern, Brian R. EOP/WHO; Benedict, Samantha; Smith, Steven M. EOP/WHO; Glaccum, David (FO); Allal,

Alale; Beckham, Hilton S. EOP/WHO; Jaeckel, Kurt; Ramplin, Meagan R

Subject: Re: Final media advisory-- 11am tomorrow

Date: Sunday, July 26, 2020 7:52:44 PM

Attachments: Event Media Advisory_Kodak_7.26.2020 FINAL.docx

All:

Attached is the final media advisory - I made an additional modification -- Jim's title is

Executive Chairman and CEO.

As stated earlier, Kodak will send to local press contacts at 11am EST.

Please let us know if you have any questions. dg

From: Horstman, John H. EOP/WHO <

Sent: Sunday, July 26, 2020 7:36 PM

To: Allen, Laura (OEA) <

Cc: Goldbarg, Denisse < Bell, Olivia (OEA) <

Burke, Amanda (OEA) < Meiners, Molly (OEA) <

Bulgrin, Julie < Baitel, Rachael (FO) < Continenza,

James V < Farah, Alyssa A. EOP/WHO <

Daravi, Roma S. EOP/WHO <

< Morgenstern, Brian R. EOP/WHO

< Benedict, Samantha < Smith,

Steven M. EOP/WHO < Glaccum, David (FO)

< Allal, Alale < Beckham, Hilton S. EOP/WHO

< Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Final media advisory-- 11am tomorrow

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Please BCC Hilton and I and we will share with our NY list.

Sent from my iPhone

On Jul 26, 2020, at 7:34 PM, Allen, Laura (OEA) < wrote:

All- flagging the final media advisory. Please see attached (and note that Governor

B028

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cuomo’s staff prefers to advise his participation to the press on Tuesday so he is not

included in this advisory).

Denisse will send out the advisory at 11am tomorrow morning; DFC will then share it

with our press list.

Let us know if you have any questions before tomorrow.

Many thanks,

Laura Allen

Press Secretary

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, D.C. 20527

m. + |

From: Goldbarg, Denisse <

Sent: Sunday, July 26, 2020 10:15 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO

< Morgenstern,

Brian R. EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Update on Planning for DFC/Kodak Event

Any update on the timing of receiving the press release? dg

From: Bell, Olivia (OEA) <

Sent: Saturday, July 25, 2020 10:48 AM

To: Goldbarg, Denisse < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

(b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
< Daravi, Roma S. EOP/WHO

<

< Morgenstern, Brian R. EOP/WHO

< Benedict, Samantha

<

< Glaccum, David (FO) <

Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: RE: Update on Planning for DFC/Kodak Event

NOTICE: External eMail. NEVER enter passwords. Only click links if you know

the sender and content are safe.

Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued

support. Please find a draft media advisory attached (with placeholders for a couple

logistical items that Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO

< Morgenstern,

Brian R. EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal

specific requirements please let us know

<Event Media Advisory_Kodak_7.26.2020 v6.docx>

(b) (6) (b) (6)
From: Burke, Amanda (OEA)

To: Goldbarg, Denisse; Vincent Esposito (esd.ny.gov); Baitel, Rachael (FO); Glaccum, David (FO); Thomas, Erin CIV

SD

Cc: Bell, Olivia (OEA); Meiners, Molly (OEA); Allen, Laura (OEA)

Subject: Tues. Run of Show

Date: Sunday, July 26, 2020 8:24:56 PM

Attachments: Run of Show 072820 DFC-Kodak 07262020 830 pm version.doc

Folks,

Good meeting you guys today. Here is the latest run of show.

Best,

Amanda

Amanda M. Burke

Deputy Vice President of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + | 

Investing in Development | dfc.gov

B029

(b) (6) (b) (6) (b) (6)
From: Allen, Laura (OEA)

To: Goldbarg, Denisse; Horstman, John H. EOP/WHO

Cc: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Bulgrin, Julie; Baitel, Rachael (FO); Continenza,

James V; Farah, Alyssa A. EOP/WHO; Daravi, Roma S. EOP/WHO; 

Morgenstern, Brian R. EOP/WHO; Benedict, Samantha; Smith, Steven M. EOP/WHO; Glaccum, David (FO); Allal,

Alale; Beckham, Hilton S. EOP/WHO; Jaeckel, Kurt; Ramplin, Meagan R

Subject: RE: Final media advisory-- 11am tomorrow

Date: Sunday, July 26, 2020 9:56:51 PM

Attachments: Event Media Advisory_Kodak_7.26.2020 FINAL_updated.docx

All- one final update to the time on the advisory—John, we’ll cc you and Hilton when it goes out

from DFC and also flag it for this chain so it can be shared with your lists.

Many thanks,

Laura Allen

Press Secretary

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, D.C. 20527

m. + |

From: Goldbarg, Denisse <

Sent: Sunday, July 26, 2020 7:52 PM

To: Horstman, John H. EOP/WHO < Allen, Laura (OEA)

<

Cc: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V < Farah,

Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Smith, Steven M. EOP/WHO <

Glaccum, David (FO) < Allal, Alale < Beckham, Hilton

S. EOP/WHO < Jaeckel, Kurt <

Ramplin, Meagan R <

Subject: Re: Final media advisory-- 11am tomorrow

All:

Attached is the final media advisory - I made an additional modification -- Jim's title is

Executive Chairman and CEO.

As stated earlier, Kodak will send to local press contacts at 11am EST.

Please let us know if you have any questions. dg

B030

(b) (6) (b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Horstman, John H. EOP/WHO <

Sent: Sunday, July 26, 2020 7:36 PM

To: Allen, Laura (OEA) <

Cc: Goldbarg, Denisse < Bell, Olivia (OEA) <

Burke, Amanda (OEA) < Meiners, Molly (OEA) <

Bulgrin, Julie < Baitel, Rachael (FO) < Continenza,

James V < Farah, Alyssa A. EOP/WHO <

Daravi, Roma S. EOP/WHO <

< Morgenstern, Brian R. EOP/WHO

< Benedict, Samantha < Smith,

Steven M. EOP/WHO < Glaccum, David (FO)

< Allal, Alale < Beckham, Hilton S. EOP/WHO

< Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Final media advisory-- 11am tomorrow

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Please BCC Hilton and I and we will share with our NY list.

Sent from my iPhone

On Jul 26, 2020, at 7:34 PM, Allen, Laura (OEA) < wrote:

All- flagging the final media advisory. Please see attached (and note that Governor

Cuomo’s staff prefers to advise his participation to the press on Tuesday so he is not

included in this advisory).

Denisse will send out the advisory at 11am tomorrow morning; DFC will then share it

with our press list.

Let us know if you have any questions before tomorrow.

Many thanks,

Laura Allen

Press Secretary

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, D.C. 20527

m. +

(b) (6)

|

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Goldbarg, Denisse <

Sent: Sunday, July 26, 2020 10:15 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO

< Morgenstern,

Brian R. EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Update on Planning for DFC/Kodak Event

Any update on the timing of receiving the press release? dg

From: Bell, Olivia (OEA) <

Sent: Saturday, July 25, 2020 10:48 AM

To: Goldbarg, Denisse < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO

<

< Morgenstern, Brian R. EOP/WHO

< Benedict, Samantha

<

< Glaccum, David (FO) <

Allal, Alale <

Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: RE: Update on Planning for DFC/Kodak Event

NOTICE: External eMail. NEVER enter passwords. Only click links if you know

the sender and content are safe.

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)(b) (6) (b) (6)
Denisse –

Thanks so much for re-sharing these items in one place and for your team’s continued

support. Please find a draft media advisory attached (with placeholders for a couple

logistical items that Kodak will have to add). We’ll share a draft press release soonest.

Many thanks again,

Olivia

Olivia Bell

Office of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + |

Investing in Development | dfc.gov

From: Goldbarg, Denisse <

Sent: Saturday, July 25, 2020 7:02 AM

To: Bell, Olivia (OEA) < Burke, Amanda (OEA)

< Meiners, Molly (OEA) < Allen,

Laura (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V

< Horstman, John H. EOP/WHO

< Farah, Alyssa A. EOP/WHO

< Daravi, Roma S. EOP/WHO

< Morgenstern,

Brian R. EOP/WHO < Benedict, Samantha

< Glaccum, David (FO)

< Allal, Alale <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cc: Jaeckel, Kurt < Ramplin, Meagan R

<

Subject: Re: Update on Planning for DFC/Kodak Event

Warning: External

To ensure everyone has all of the information, I have attached 3 several files.

1. Photo of the Kodak theater where the signing will take place

2. Floor plan of the Kodak theater

3. Kodak talking points and quote from CEO Jim Continenza.

To come later today: updated run of show including the tour of the facility.

Whats missing:

1. Draft of media advisory

2. Final confirmation of number of attendees -- currently at 8

3. Kodak guest list

In parallel we are working on signage and AV requirements. If you have additoinal

specific requirements please let us know

<Event Media Advisory_Kodak_7.26.2020 v6.docx>

(b) (6) (b) (6)
From: Goldbarg, Denisse

To: Burke, Amanda (OEA)

Cc: Vincent Esposito (esd.ny.gov); Baitel, Rachael (FO); Glaccum, David (FO); Thomas, Erin CIV SD; Bell, Olivia

(OEA); Meiners, Molly (OEA); Allen, Laura (OEA)

Subject: Re: Tues. Run of Show

Date: Monday, July 27, 2020 6:30:19 AM

Thank you -- I ask because it will determine how many Kodak employees we can invite.

dg

From: Burke, Amanda (OEA) <

Sent: Monday, July 27, 2020 4:09 AM

To: Goldbarg, Denisse <

Cc: Vincent Esposito (esd.ny.gov) < Baitel, Rachael (FO)

< Glaccum, David (FO) < Thomas, Erin CIV SD

< Bell, Olivia (OEA) < Meiners, Molly (OEA)

< Allen, Laura (OEA) <

Subject: Re: Tues. Run of Show

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

With speakers, staff, security, and a few others, we may be at 30-ish.

.................................................................................

Amanda M. Burke

Deputy Vice President of External Affairs

U.S. International Development Finance Corporation

Visit us at www.dfc.gov

On Jul 26, 2020, at 23:07, Goldbarg, Denisse <

wrote:

Warning: External

Do you have a total number at attendees at the Kodak Center? dg

From: Burke, Amanda (OEA) <

Sent: Sunday, July 26, 2020 8:23 PM

To: Goldbarg, Denisse < Vincent Esposito (esd.ny.gov)

< Baitel, Rachael (FO) <

B031

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Glaccum, David (FO) < Thomas, Erin CIV SD

<

Cc: Bell, Olivia (OEA) < Meiners, Molly (OEA)

< Allen, Laura (OEA) <

Subject: Tues. Run of Show

NOTICE: External eMail. NEVER enter passwords. Only click links if you know

the sender and content are safe.

Folks,

Good meeting you guys today. Here is the latest run of show.

Best,

Amanda

Amanda M. Burke

Deputy Vice President of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + | 

Investing in Development | dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Burke, Amanda (OEA)

To: Esposito, Vincent (ESD); "Goldbarg, Denisse"; Baitel, Rachael (FO); Glaccum, David (FO); "Thomas, Erin CIV SD"

Cc: Bell, Olivia (OEA); Meiners, Molly (OEA); Allen, Laura (OEA)

Subject: RE: Tues. Run of Show

Date: Monday, July 27, 2020 8:52:56 AM

Yes, he will mention it in his remarks.

From: Esposito, Vincent (ESD) <

Sent: Monday, July 27, 2020 8:09 AM

To: Burke, Amanda (OEA) < 'Goldbarg, Denisse'

< Baitel, Rachael (FO) < Glaccum, David

(FO) < 'Thomas, Erin CIV SD' <

Cc: Bell, Olivia (OEA) < Meiners, Molly (OEA) < Allen,

Laura (OEA) <

Subject: RE: Tues. Run of Show

Thanks Amanda. With the new program order, can you confirm that Adam B will announce the DFCKodak loan before Gov Cuomo speaks? Thanks, -Vinnie

From: Burke, Amanda (OEA) <

Sent: Sunday, July 26, 2020 8:24 PM

To: Goldbarg, Denisse < Esposito, Vincent (ESD)

< Baitel, Rachael (FO) < Glaccum, David (FO)

< Thomas, Erin CIV SD <

Cc: Bell, Olivia (OEA) < Meiners, Molly (OEA) < Allen,

Laura (OEA) <

Subject: Tues. Run of Show

ATTENTION: This email came from an external source. Do not open attachments or click on links from

unknown senders or unexpected emails.

Folks,

Good meeting you guys today. Here is the latest run of show.

Best,

Amanda

Amanda M. Burke

Deputy Vice President of External Affairs

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, DC 20527

o. + | m. + | 

B032

(b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Investing in Development | dfc.gov

IMPORTANT: This e-mail message and any attachments contain information intended for the

exclusive use of the individual(s) or entity to whom it is addressed and may contain information that

is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are

not the intended recipient, you are hereby notified that any viewing, copying, disclosure or

distribution of this information may be subject to legal restriction or sanction. Please immediately

notify the sender by electronic mail or notify the System Administrator by telephone 

or e-mail ( and delete the message. Thank you.

(b) (6) (b) (6)
From: Olson, Ramin (PO)

To:

Cc: Allal, Alale

Subject: Contact information

Date: Monday, July 27, 2020 11:14:00 AM

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

B033

(b) (6) (b) (6)(b) (6)
From: Byrd, Roger W

To: Olson, Ramin (PO); Allal, Alale

Cc: Continenza, James V

Subject: Revised Term Sheet

Date: Monday, July 27, 2020 11:34:33 AM

Attachments: image001.png

Kodak Pharmaceuticals Inc. - DFC PF Term Sheet for DPA Loan -Kodak Comments - 7.27.2020 as

Negotiated.docx

Kodak Pharmaceuticals Inc. - DFC PF Term Sheet for DPA Loan -Kodak Comments - 7.27.2020 Marked.docx

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

B034

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6)
From: Allen, Laura (OEA)

To: Goldbarg, Denisse; Beckham, Hilton S. EOP/WHO; Horstman, John H. EOP/WHO

Cc: Bell, Olivia (OEA); Burke, Amanda (OEA); Meiners, Molly (OEA); Bulgrin, Julie; Baitel, Rachael (FO); Continenza,

James V; Farah, Alyssa A. EOP/WHO; Daravi, Roma S. EOP/WHO; 

Morgenstern, Brian R. EOP/WHO; Benedict, Samantha; Smith, Steven M. EOP/WHO; Glaccum, David (FO); Allal,

Alale; Jaeckel, Kurt; Ramplin, Meagan R

Subject: RE: Final media advisory-- 11am tomorrow

Date: Monday, July 27, 2020 11:46:04 AM

Attachments: image001.png

Great-- Thank you, Denisse. We are forwarding to our list now.

Laura Allen

Press Secretary

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue Northwest | Washington, D.C. 20527

m. + |

From: Goldbarg, Denisse <

Sent: Monday, July 27, 2020 11:44 AM

To: Beckham, Hilton S. EOP/WHO < Allen, Laura (OEA)

< Horstman, John H. EOP/WHO <

Cc: Bell, Olivia (OEA) < Burke, Amanda (OEA) <

Meiners, Molly (OEA) < Bulgrin, Julie < Baitel,

Rachael (FO) < Continenza, James V < Farah,

Alyssa A. EOP/WHO < Daravi, Roma S. EOP/WHO

< Morgenstern, Brian R.

EOP/WHO < Benedict, Samantha

< Smith, Steven M. EOP/WHO <

Glaccum, David (FO) < Allal, Alale < Jaeckel, Kurt

< Ramplin, Meagan R <

Subject: Re: Final media advisory-- 11am tomorrow

Warning: External

Below is the media alert that went out. We sent them out individually to each journalist that

was on our list that we provided.

Let us know if you have any questions. dg

From: "Wagner, Chelsea R" <

Date: Monday, July 27, 2020 at 11:29 AM

B035

(b) (6) (b) (6) (b) (6)(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
To: " <

Subject: MEDIA ALERT: 7/28 @ 4 PM - Kodak, DFC to Announce COVID-19 Manufacturing

Initiative

Hi Randy,

See below for details on a press event tomorrow, where Kodak Executive Chairman Jim Continenza

and senior U.S. government officials will announce a major manufacturing initiative that will have a

significant impact on Rochester and the American people.

Please let me know if you plan on attending, or if you have any questions.

Thanks!

Chelsea

MEDIA ADVISORY

Contact: Chelsea Wagner, PR Manager, Kodak

For Immediate Release

 

 

Kodak, DFC to Announce COVID-19 Manufacturing Initiative

ROCHESTER, NY, July 27, 2020— Eastman Kodak Company (Kodak) Executive

Chairman and Chief Executive Officer Jim Continenza will be joined by senior government

leaders to unveil a new manufacturing initiative with U.S. International Development Finance

Corporation (DFC) in response to the COVID-19 pandemic.

WHO: Kodak Executive Chairman and Chief Executive Officer Jim Continenza

DFC CEO Adam Boehler

 Assistant to the President and Director of the Office of Trade and

Manufacturing

Policy Dr. Peter Navarro

 Deputy Secretary of Defense David Norquist

 Rear Admiral John Polowczyk

 

WHAT: Announcement of new manufacturing initiative

WHERE: Kodak Center

 200 W Ridge Rd, Rochester, NY 14615 

WHEN: Tuesday, July 28, 2020; 4:00 p.m.; preset time for media cameras is 3:15 p.m.

RSVP: Chelsea Wagner, PR Manager, Kodak

(b) (6)(b) (6) (b) (6) (b) (6)
Please note: To ensure the safety of our attendees and guests, we ask that you maintain social

distance, wear a face covering and sit only in designated seats in the theatre.

Chelsea Wagner | PR Manager| WW Communications

Eastman Kodak Company

| m 

www.kodak.com

(b) (6) (b) (6)
From: Olson, Ramin (PO)

To: Byrd, Roger W; Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 1:42:00 PM

Attachments: image001.png

Roger, I’ll check internally and get back to you on which documents will be executable.

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

B036

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6) (b) (6) (b) (6)
From: Olson, Ramin (PO)

To: Byrd, Roger W; Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 2:25:00 PM

Attachments: LOI - Kodak v02 (7.27.2020).docx

image001.png

Roger,

As just discussed, please see attached Draft LOI.

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

B037

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6)
From: Olson, Ramin (PO)

To: Byrd, Roger W

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 2:57:00 PM

Attachments: image001.png

Roger,

I called you to follow up on this, but you’re already gone to your meeting. Please call me if you

would like to discuss. Thank you.

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Olson, Ramin (PO) 

Sent: Monday, July 27, 2020 2:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Roger,

As just discussed, please see attached Draft LOI.

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

B038

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Olson, Ramin (PO)

To: Byrd, Roger W; Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 3:30:00 PM

Attachments: image001.png

LOI - Kodak v03 (7.27.2020).docx

Roger,

As discussed, please see an updated draft of the LOI referencing the term sheet. The formatting is

thrown off by the added line, but we will fix that on this end.

Please call me if any questions.

Regards, 

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

B039

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Byrd, Roger W

To: Olson, Ramin (PO); Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 5:39:33 PM

Attachments: image001.png

LOI - Kodak 7.27.2020 RB Comments.docx

Thanks Ramin. My comments on the letter are reflected in tracked changes in the attached. I have

not fully vetted this within Kodak, but wanted to get you my input as soon as possible. It is possible,

but unlikely, that we may have some additional input. Please let me know if you have any concerns

with my proposed changes. I am happy to discuss if that would be helpful. Best,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 3:30 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, please see an updated draft of the LOI referencing the term sheet. The formatting is

thrown off by the added line, but we will fix that on this end.

Please call me if any questions.

Regards, 

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

B040

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6)
From: Olson, Ramin (PO)

To: Byrd, Roger W; Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO); Burke, Amanda (OEA)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 5:57:00 PM

Attachments: image001.png

LOI - Kodak 7.27.2020 v.FINAL.docx

Roger,

As discussed, the final version is attached. All changes accepted except for the clause at the end of

the first full paragraph.

Regards,

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 5:39 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. My comments on the letter are reflected in tracked changes in the attached. I have

not fully vetted this within Kodak, but wanted to get you my input as soon as possible. It is possible,

but unlikely, that we may have some additional input. Please let me know if you have any concerns

with my proposed changes. I am happy to discuss if that would be helpful. Best,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 3:30 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

B041

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, please see an updated draft of the LOI referencing the term sheet. The formatting is

thrown off by the added line, but we will fix that on this end.

Please call me if any questions.

Regards, 

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Byrd, Roger W

To: Olson, Ramin (PO); Allal, Alale

Cc: Continenza, James V; Glaccum, David (FO); Burke, Amanda (OEA)

Subject: RE: Revised Term Sheet

Date: Monday, July 27, 2020 6:22:02 PM

Attachments: image001.png

Thanks Ramin. This looks fine to me. I am just trying to connect with Jim to make sure he is ok and

will give final sign-off as soon as I have connected with him.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 5:58 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

< Burke, Amanda (OEA) <

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, the final version is attached. All changes accepted except for the clause at the end of

the first full paragraph.

Regards,

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 5:39 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

B042

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
<

Subject: RE: Revised Term Sheet

Thanks Ramin. My comments on the letter are reflected in tracked changes in the attached. I have

not fully vetted this within Kodak, but wanted to get you my input as soon as possible. It is possible,

but unlikely, that we may have some additional input. Please let me know if you have any concerns

with my proposed changes. I am happy to discuss if that would be helpful. Best,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 3:30 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, please see an updated draft of the LOI referencing the term sheet. The formatting is

thrown off by the added line, but we will fix that on this end.

Please call me if any questions.

Regards, 

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6)
From: Allal, Alale

To: Olson, Ramin (PO); Byrd, Roger W

Cc: Continenza, James V; Glaccum, David (FO); Burke, Amanda (OEA)

Subject: Re: Revised Term Sheet

Date: Monday, July 27, 2020 6:42:02 PM

Attachments: image001.png

Thanks, Roger. Have a good night. 

Best regards, 

Alale Allal 

Export Finance Director 

Office of International Trade 

U.S. Small Business Administration 

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 6:40:32 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

< Burke, Amanda (OEA) <

Subject: RE: Revised Term Sheet

CAUTION - The sender of this message is external to the SBA network. Please use care when

clicking on links and responding with sensitive information. Send suspicious email to

Kodak is fully signed off on the LOI. Best,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 5:58 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

< Burke, Amanda (OEA) <

Subject: RE: Revised Term Sheet

B043

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, the final version is attached. All changes accepted except for the clause at the end of

the first full paragraph.

Regards,

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 5:39 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. My comments on the letter are reflected in tracked changes in the attached. I have

not fully vetted this within Kodak, but wanted to get you my input as soon as possible. It is possible,

but unlikely, that we may have some additional input. Please let me know if you have any concerns

with my proposed changes. I am happy to discuss if that would be helpful. Best,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 3:30 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

As discussed, please see an updated draft of the LOI referencing the term sheet. The formatting is

thrown off by the added line, but we will fix that on this end.

Please call me if any questions.

Regards, 

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 1:38 PM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

<

Subject: RE: Revised Term Sheet

Thanks Ramin. Do you have a sense of timing on the draft of the letter of intent? We will stand by

and review that when it is available.

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 1:26 PM

To: Byrd, Roger W < Allal, Alale <

Cc: Continenza, James V < Glaccum, David (FO)

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
<

Subject: RE: Revised Term Sheet

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

Thank you. This draft looks fine. I believe the final Term Sheet will be attached to a letter of intent

from us, so no need to turn this into an executable document right now. Our team will confirm that

and follow up with you on that point later.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) | | www.dfc.gov

From: Byrd, Roger W <

Sent: Monday, July 27, 2020 11:34 AM

To: Olson, Ramin (PO) < Allal, Alale <

Cc: Continenza, James V <

Subject: Revised Term Sheet

Warning: External

Ramin/Alale,

It was nice speaking with you (and meeting you Ramin) this morning. Attached is a revised draft of

the Term Sheet that incorporates our discussion and my subsequent conversation with Alale. Based

on our discussion of referring to the proxy statement for 10% owners, I removed the ownership

diagram as well. A cumulative marked copy showing the changes to Ramin’s last draft is also

attached. Please reach out to me if there are any questions. I did not convert this into an

executable document—do you contemplate there being a letter to which this will be attached or do

you plan to have this be the actual document that is signed? Please let me know how you plan to

proceed and if I need to generate anything in that regard. Thanks,

Roger W. Byrd

General Counsel, Secretary & Senior Vice President |

EASTMAN KODAK COMPANY | 343 State Street | Rochester, NY 14650-0208 |

 | Office | Mobile |

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
www.kodak.com

From: Olson, Ramin (PO) <

Sent: Monday, July 27, 2020 11:15 AM

To: Byrd, Roger W <

Cc: Allal, Alale <

Subject: Contact information

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Roger,

My contact information, FYI, below.

Regards,

Ramin

Ramin Olson

Office of Strategic Initiatives

U.S. International Development Finance Corporation (DFC)

1100 New York Avenue NW | Washington, DC 20527

c: (+1) 

(b) (6)

 | | www.dfc.gov

(b) (6) (b) (6) (b) (6) (b) (6)
From: Taber, Terry [Terry] R

To: Allal, Alale

Subject: FW: Business Plan

Date: Monday, July 27, 2020 6:56:55 PM

Attachments: image001.png

Eastman Kodak Company- DFC Application Business Plan June 26.pdf

Warning: External

Alale,

Here you go....

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Taber, Terry [Terry] R 

Sent: Monday, July 27, 2020 6:04 PM

To: Allal, Alale <

Subject: Business Plan

Alale,

Attached is the business plan as you requested.

Hope all is well.

Best,

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

B044

(b) (6) (b) (6) (b) (6) (b) (6)
1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Gutkin, Paula J <

Sent: Monday, July 27, 2020 5:22 PM

To: Taber, Terry [Terry] R <

Subject: Business Plan and Financials

This is the business plan and financial model that were submitted.

Paula J. Gutkin | Managing Director, Corporate Development

Eastman Kodak Company

| m (PLEASE NOTE NEW TELEPHONE NUMBER)

www.kodak.com

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Allal, Alale

To: Taber, Terry [Terry] R

Subject: Re: Business Plan

Date: Monday, July 27, 2020 7:10:08 PM

Attachments: image001.png

Recieved. Thanks!

Sent via the Samsung Galaxy Note9, an AT&T 5G Evolution capable smartphone

Get Outlook for Android

From: Taber, Terry [Terry] R <

Sent: Monday, July 27, 2020 6:56:14 PM

To: Allal, Alale <

Subject: FW: Business Plan

Warning: External

Alale,

Here you go....

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Taber, Terry [Terry] R 

Sent: Monday, July 27, 2020 6:04 PM

To: Allal, Alale <

Subject: Business Plan

Alale,

Attached is the business plan as you requested.

Hope all is well.

B045

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Best,

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

From: Gutkin, Paula J <

Sent: Monday, July 27, 2020 5:22 PM

To: Taber, Terry [Terry] R <

Subject: Business Plan and Financials

This is the business plan and financial model that were submitted.

Paula J. Gutkin | Managing Director, Corporate Development

Eastman Kodak Company

| m (PLEASE NOTE NEW TELEPHONE NUMBER)

www.kodak.com

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Continenza, James V

To: Glaccum, David (FO)

Cc: Allal, Alale

Subject: Re: Kodak

Date: Tuesday, July 28, 2020 9:19:07 AM

Warning: External

David, I can’t thank you and Allal Enough not just for Kodak I am also Honored to be part of

fixing the pharmaceutical supply chain in America and we couldn’t of done this without you

guys.

Looking forward to meeting you also.

Jim

This country is so lucky to have a group like the DFC to help bridge government and

businesses to work together.

Get Outlook for iOS

From: Glaccum, David (FO) <

Sent: Tuesday, July 28, 2020 8:32:36 AM

To: Continenza, James V <

Cc: Allal, Alale <

Subject: Kodak

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Jim,

Hope you are well. Great coverage this morning. I look forward to meeting in person today.

Thanks for having us up.

Talk soon.

DMG

B046

(b) (6) (b) (6) (b) (6)
From: Glaccum, David (FO)

To: Meiners, Molly (OEA); Goldbarg, Denisse

Subject: Re: Connecting on Process

Date: Tuesday, July 28, 2020 11:40:37 AM

Thanks, Molly.

Denisse - happy to discuss. 

From: Meiners, Molly (OEA) <

Sent: Tuesday, July 28, 2020 11:39:48 AM

To: Glaccum, David (FO) < Goldbarg, Denisse

<

Subject: Connecting on Process

David - I’m connecting you with Denisse, who runs comms and marketing for Kodak. She has

some questions about process (and is getting inbounds from reporters). I sent her the flow

chart + qualifications you created, but it might be helpful if you two can speak directly.

Get Outlook for iOS

B047

(b) (6) (b) (6) (b) (6) (b) (6)

From: Goldbarg, Denisse

To: Meiners, Molly (OEA)

Cc: Glaccum, David (FO); Allen, Laura (OEA)

Subject: Re: Connecting with Kodak

Date: Thursday, July 30, 2020 3:47:32 PM

Any update -- need to get back to her. I will reiterate that Kodak has yet to receive the loan

and will use the language you provided below. dg

From: Meiners, Molly (OEA) <

Sent: Thursday, July 30, 2020 3:13 PM

To: Goldbarg, Denisse <

Cc: Glaccum, David (FO) < Allen, Laura (OEA) <

Subject: Re: Connecting with Kodak

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender

and content are safe.

Hi Denisse - We have been asked for some specifics around the loan, but largely it isn’t

something we provide at this point in the process.

David, Laura - believe you were asked about this by Bloomberg yesterday. Any

recommendations on how to handle?

Also, this could be a good opportunity to remind Rachael that the loan is not

finalized/approved. We signed a letter of interest and the loan is still going through DFC’s

approval process. As we note in the press release:

The LOI that will be signed today indicates Kodak’s successful completion of

DFC’s initial screening and will be followed by standard due diligence

conducted by the agency before financing is formally committed.

Molly Millerwise Meiners

Chief Communications Officer

U.S. International Development Finance Corporation

Visit us at www.dfc.gov

On Jul 30, 2020, at 3:02 PM, Goldbarg, Denisse <

wrote:

Warning: External

B049

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Molly:

Rachel is asking for details of the loan. What is the DFC sharing publicly if

anything? Has she already asked you? dg

From: Levy, Rachael <

Sent: Thursday, July 30, 2020 2:59 PM

To: Goldbarg, Denisse <

Subject: Re: Connecting with Kodak

NOTICE: External eMail. NEVER enter passwords. Only click links if you know

the sender and content are safe.

Hi Denisse, hope you're well. I just wanted to circle back re: my request for the

loan specifics. Were you able to get them? Thanks so much.

Rachael Levy

REPORTER

 (Mobile, Signal, WhatsApp)

Read my stories here.

(b) (6) (b) (6) (b) (6) (b) (6)
From: Meiners, Molly (OEA)

To: Goldbarg, Denisse

Cc: Glaccum, David (FO); Allen, Laura (OEA)

Subject: Re: Connecting with Kodak

Date: Thursday, July 30, 2020 4:19:29 PM

Got it. Thanks, Denisse.

FYI, Rachael just emailed Adam and Navarro asking for an interview on DPA and other

potential projects. No real mention of Kodak in her request.

Molly Millerwise Meiners

Chief Communications Officer

U.S. International Development Finance Corporation

Visit us at www.dfc.gov

On Jul 30, 2020, at 4:04 PM, Goldbarg, Denisse <

wrote:

Thanks all. I reiterated that we have not received the loan and used the language

from the release release about where we are in the process. dg

From: Glaccum, David (FO) <

Sent: Thursday, July 30, 2020 3:47 PM

To: Meiners, Molly (OEA) < Goldbarg, Denisse

<

Cc: Allen, Laura (OEA) <

Subject: Re: Connecting with Kodak

NOTICE: External eMail. NEVER enter passwords. Only click links if you know

the sender and content are safe.

Thanks, Molly. Correct, we have not shared details of the term sheet with anyone

outside of the USG. Bloomberg even noted in their article that Adam and I would

give them specifics. 

I also wouldnt recommend it because they could change during the remaining

steps of the process, but let us know either way.

From: Meiners, Molly (OEA) <

B050

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
Sent: Thursday, July 30, 2020 3:42 PM

To: Goldbarg, Denisse

Cc: Glaccum, David (FO); Allen, Laura (OEA)

Subject: Re: Connecting with Kodak

And while it isn’t financials, Rachael could also be pointed to the information we

put out (process, qualifications) as part of our request for proposals:

https://www.dfc.gov/sites/default/files/media/documents/DFC-DPA-RFP06222020_0.pdf

Molly Millerwise Meiners

Chief Communications Officer

U.S. International Development Finance Corporation

Visit us at www.dfc.gov

On Jul 30, 2020, at 3:13 PM, Meiners, Molly (OEA)

< wrote:

 Hi Denisse - We have been asked for some specifics around the loan,

but largely it isn’t something we provide at this point in the process.

David, Laura - believe you were asked about this by Bloomberg

yesterday. Any recommendations on how to handle?

Also, this could be a good opportunity to remind Rachael that the

loan is not finalized/approved. We signed a letter of interest and the

loan is still going through DFC’s approval process. As we note in the

press release:

The LOI that will be signed today indicates Kodak’s

successful completion of DFC’s initial screening and will

be followed by standard due diligence conducted by

the agency before financing is formally committed.

Molly Millerwise Meiners

Chief Communications Officer

U.S. International Development Finance Corporation

Visit us at www.dfc.gov

On Jul 30, 2020, at 3:02 PM, Goldbarg, Denisse

(b) (6)
< wrote:

Warning: External

Molly:

Rachel is asking for details of the loan. What is the DFC

sharing publicly if anything? Has she already asked you?

dg

From: Levy, Rachael <

Sent: Thursday, July 30, 2020 2:59 PM

To: Goldbarg, Denisse <

Subject: Re: Connecting with Kodak

NOTICE: External eMail. NEVER enter passwords. Only

click links if you know the sender and content are safe.

Hi Denisse, hope you're well. I just wanted to circle back

re: my request for the loan specifics. Were you able to

get them? Thanks so much.

Rachael Levy

REPORTER

 (Mobile, Signal, WhatsApp)

Read my stories here.

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)
From: Allal, Alale

To: Taber, Terry [Terry] R; Continenza, James V

Cc: Allal, Alale

Subject: FW: Description and White Papers

Date: Thursday, July 30, 2020 4:37:59 PM

Attachments: image002.png

Final.pdf

pdf

Terry,

Thanks for supplying. I still need to know the following for these products:

Cost

Timeline for being fully operational

Maximum Production/output

Your financing need and purpose to have the operation necessary to produce

Best regards,

Alale Allal

Export Finance Director, Southeast Region

Office of International Trade 

1919 Smith Street, Ste. 10087

Houston, Texas 77002

U.S. Small Business Administration

Cell 

Home Page | Twitter | Instagram | Facebook | YouTube | LinkedIn | Email Alerts

From: Allal, Alale <

Sent: Thursday, July 30, 2020 3:34 PM

To: Allal, Alale <

Subject: FW: Description and White Papers

CAUTION - The sender of this message is external to the SBA network. Please use care when

clicking on links and responding with sensitive information. Send suspicious email to

B051

Attachments duplicative with B048.

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4) (b) (4)
Best regards,

Alale Allal

Project Finance Manager

U.S. International Development Finance Corporation (DFC)

o. + |

Investing in Development | dfc.gov

From: Taber, Terry [Terry] R <

Sent: Wednesday, July 29, 2020 10:29 PM

To: Allal, Alale <

Cc: Continenza, James V <

Subject: Description and White Papers

Warning: External

Alale,

The attachments include an overview that describes the 

and two white papers submitted to a few years

ago (one on and the other on 

Although the conversation has advanced beyond this first request from

earlier this evening, I still wanted to provide you the documents as

promised.

Best,

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
From: Taber, Terry [Terry] R

To: Allal, Alale

Cc: Continenza, James V

Subject: Status document

Date: Thursday, July 30, 2020 8:32:35 PM

Attachments: image002.png

.pdf

Warning: External

Alale,

Here is the document you requested. Thank you.

Terry

Terry R. Taber, Ph.D.

Chief Technical Officer & VP, Kodak

SVP, Advanced Materials & Chemicals

1999 Lake Avenue, Rochester, N.Y. 14650-2210

 |Office: | Mobile: 

www.kodak.com

B052

(b) (6) (b) (6) (b) (6) (b) (4)
TEMPLATE LAST REVISED ON: 1/1/2020

This document is subject to the terms of the Disclaimer Stateme

Enter Project/Company Name

 

9/1/2020

Eastman Kodak

Enter Target Date for 

First Disbursement of 

DFC-Supported Debt
ent in Article I of the Business Plan to which this financial information relates.
Project Assumptions

Calendar Year 2020 2021 2022 2

Eastman Kodak

Revenues in $000s

High Volume APIsNumber of Units sold annually Kilograms

Price per Unit (local currency)Currency conversion (local currency per USD)High Volume APIs Revenue in $000sSPIR Warehousing RevenueNumber of Units sold annually Square Feet

Price per Unit (local currency)Currency conversion (local currency per USD)SPIR Warehousing Revenue Revenue in $000sReagentsNumber of Units sold annually Liters

Price per Unit (local currency)Currency conversion (local currency per USD)Reagents Revenue in $000s

Non-Regulated KSMsNumber of Units sold annually Kilograms

Price per Unit (local currency)Currency conversion (local currency per USD)Non-Regulated KSMs Revenue in $000sLow Volume APIsNumber of Units sold annually KilogramsPrice per Unit (local currency)Currency conversion (local currency per USD)Low Volume APIs Revenue in $000sCost of Goods Sold as % of Total Sales Revenue

Cost of Goods Sold in $000s

Operating Costs in $000s

Total Sales Revenues in $000s

9/2/2020 4:08 PM Page 3 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2

Indirect/Overhead Costs

Local Currency Costs

Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Total Local Currency Cost (local 000s) 

Conversion (local currency per USD)

Total Local currency cost in $000s 

US Dollar Costs

Startup, Accreditation and other one-time ItemsResearch and DevelopmentDirect SG&ACorporate Functions

Research Labs Facility Costs (net of lease income) 

Total US Dollar Costs ($000s)

Total Indirect Costs ($000s)

9/2/2020 4:08 PM Page 4 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2

Capital Costs in $000s

Capital Expenditures (Up-front costs)

Construction of SAPIR Warehouse 

IT Systems for SAPIR Warehouse 

Construction of Hybrid Manufacturing Facility

Equipment for Hybrid Manufacturing Facility 

IT Systems for Hybrid Manufacturing Facility

Renovation of facility for Center of Excellence 

Equipment for Center of Excellence 

IT Systems for Center of Excellence 

Renovation for reagent manufacturing facilities 

Equipment for reagent manufacturing facilities 

IT Systems for reagent manufacturing facilities

Assets Contributed

Ongoing Cap Ex

rement Essential Medicines for Shortage - Not Depreciated

DFC Debt Assumptions and Schedule

Total Loan Amount in $000sBase Interest Cost (%)Interest Risk Spread (%) 0.00%

All-in Annual Interest Rate (%)

Commitment Fee (%) 0.00%Facility/Administrative Fee (%) 0.00%

Total Loan Term (months) 300Grace Period on Principal Repayment (months)# of payments per year

Estimated Date of First Drawdown 09/01/20Estimated Date of First Principal Repayment

Estimated Maturity Date 09/01/45Number of Principal PaymentsStraight-line or Mortgage-Style?# of principal Payments if quarterly 000# of principal Payments if semi-annual 000

000

Outstanding Principal (Start of Year)DFC Debt Principal Disbursements in $000s DFC Debt Fees (Facility, Commitment) 

Total Annual Capital Expenditures

Base Interest Cost is usually the Umaturity or another internationally-DFC contact.For Straightline, enter "1"; For MorDFC rarely allows mortgage-style before choosing option "2".

Enter "2" for semi-annual; Enter "

9/2/2020 4:08 PM Page 5 Eastman Kodak Financial Projection

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2DFC Debt Interest DFC Debt Principal Repayments 

Total DFC Debt Service 

Outstanding Principal (End of Year)

Other Senior Debt -- Assumptions and Schedule

Name of LenderAnnual Interest Rate (%) 0%Outstanding Principal (Start of Year) 000Principal Disbursements (in $000s) 000Fees (in $000s) 000Interest 000Principal Repayments (in $000s) 000

Total Other Senior Debt Service 000

Outstanding Principal (End of Year) 000

Name

Note: Multiple senior debt sources aPlease consult your DFC contact befsenior debt sources.

9/2/2020 4:08 PM Page 6 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2

Short Term Debt -- Assumptions and Schedule

Name of LenderAnnual Interest Rate (%) 0%Outstanding Principal (Start of Year) 000Principal Disbursements (in $000s) 000Fees (in $000s) 000Interest 000Principal Repayments (in $000) 000

Total Short Term Debt Service 000

Outstanding Principal (End of Year) 000

Subordinated Debt -- Assumptions and Schedule

Name of LenderOutstanding Principal (Start of Year) 000Principal Disbursements ($000s) 000Fees or Interest (if allowed) ($000s) 000Principal Repayments ($000s) 000

Total Subordinated Debt Service 000

Outstanding Principal (End of Year) 000

Equity and Reconciliation of Retained Earnings

Equity (Start of Year) in $000sNew Equity Contributions in $000sEquity (End of Year)Retained Earnings (Start of Year)Net IncomeDividend Payout Ratio (%)Dividends Paid Retained Earnings (End of Year)

Income Tax Assumptions

Tax Rate 0% 0% 0% 

NameName

Note: Other debt sources are not aconsult your DFC contact before madebt facilities.

Note: Some projects may structure equity as suborsomewhat unusual for an DFC-supported project, sregarding subordinated debt.

9/2/2020 4:08 PM Page 7 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2

Depreciation/Amortization Assumptions

Year Depreciation/Amortization Begins

Construction of SAPIR Warehouse

IT Systems for SAPIR Warehouse

Construction of Hybrid Manufacturing Facility

Equipment for Hybrid Manufacturing Facility

IT Systems for Hybrid Manufacturing Facility

Renovation of facility for Center of Excellence

Equipment for Center of Excellence

IT Systems for Center of Excellence

Renovation for reagent manufacturing facilities

Equipment for reagent manufacturing facilities

IT Systems for reagent manufacturing facilities

Assets Contributed

Ongoing Cap Ex

Total Annual Depreciation Exp.

9/2/2020 4:08 PM Page 8 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

Calendar Year 2020 2021 2022 2

Working Capital and Debt Service Reserve Assumpti

Days in ReceivablesDays InventoryDays in PayablesMonths Debt Service to Restricted Cash 

Cost of Capital (for Net Present Value Calculation Purposes)

Amount of DFC DebtAmount of other Senior DebtAmount of Sub-Debt/Equity

Total Project Capitalization

Cost of DebtCost of EquityWeighted Average Cost of Capital

9/2/2020 4:08 PM Page 9 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

9/2/2020 4:08 PM Page 10 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

9/2/2020 4:08 PM Page 11 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

9/2/2020 4:08 PM Page 12 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

0000000000000000000000000000000000000000000000000

9/2/2020 4:08 PM Page 13 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000

0% 0% 0% 0% 0% 0% 0%

 ebt from a 3rd party. This is 

 making any assumptions 

9/2/2020 4:08 PM Page 14 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

9/2/2020 4:08 PM Page 15 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2026 2027 2028 2029 2030 2031 2032 2033 2034 2

9/2/2020 4:08 PM Page 16 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

9/2/2020 4:08 PM Page 17 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

00000000

9/2/2020 4:08 PM Page 18 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

9/2/2020 4:08 PM Page 19 Eastman Kodak Financial Projection

(b) (4) (b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

0

9/2/2020 4:08 PM Page 20 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

0

9/2/2020 4:08 PM Page 21 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

9/2/2020 4:08 PM Page 22 Eastman Kodak Financial Projection

(b) (4)
Project Assumptions

2038 2039 2040 2041 2042 2043 2042 2043

0

9/2/2020 4:08 PM Page 23 Eastman Kodak Financial Projection

(b) (4)
Income Statement

Calendar Year 2020 2021 2022 2023 

Projected Projected Projected Projected 

Revenues 

High Volume APIs Revenue in $000sSPIR Warehousing Revenue Revenue in $000sReagents Revenue in $000sNon-Regulated KSMs Revenue in $000sLow Volume APIs Revenue in $000s

Gross Revenues

Cost of Product SoldOperating Expenses

Operating Expense (local 000s)

Operating Expense (local 000s)

Operating Expense (local 000s)

Operating Expense (local 000s)

Operating Expense (local 000s)

Startup, Accreditation and other one-time Items

Research and Development

Direct SG&A

Corporate Functions

Research Labs Facility Costs (net of lease income)

Total Operating Expenses

Gross Operating Profit (EBITDA)Depreciation Expense

EBIT

Interest & Fee Income/(Expense)Income Taxes

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Income Statement

Net IncomeDividendsAddition to Retained Earnings

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Income Statement

2026 2027 2028 2029 2030 2031 2032 2033 

Projected Projected Projected Projected Projected Projected Projected Projected 

k

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Income Statement

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Income Statement

2036 2037 2038 2039 2040 2041 2042 2043 

Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Income Statement

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Projected Projected Projected Projected Projected Projected Projected Projected Projected 

Cash Flow Statement

SalesChange in Receivables

Cash from Sales

Cost of Goods SoldChange in InventoryChange in Payables/Other Curr. Liabilities

Cash Production Costs

Gross Cash Profits

Cash Operating Expenses

Cash After Operations

Taxes Paid 

Net Cash After Operations

Capital Expenditures 

Net Cash After Investing Activities

Interest & Fee Income/(Expense) 

Dividends Paid Short Term Debt Inflow/(Outflow) LT Senior Debt Inflow/(Outflow)Subordinated Debt Inflow/(Outflow) Equity Inflow/(Outflow) 

Net Cash After Financing Activities

Beginning Cash

Change in Cash

Cash (to)/from debt reserve 

Ending Cash

Eastman Kodak

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Debt Service Coverages/Cash Available for Debt Service (CADS)

Operating Debt Service CoverageNet Cash After Operations(Operating CADS)Net Interest & Fee Expense Principal Payments

Total Debt Service

Operating CADS/Interest & FeeOperating CADS/PrincipalOperating CADS/Total Debt ServiceAverage Debt Service CoverageTotal Debt Service CoverageNet Cash Flow+Interest & Fee Expense +Principal Repayment+Dividends Paid 

Total CADS

Interest & Fee Expense 

Principal Repayment

Total Debt Service

Total CADS/Interest+FeeTotal CADS/Scheduled PrincipalTotal CADS/Total Debt ServiceAverage Debt Service Coverage

Discounted Cash Flow (DCF)/Net Present Value (NPV) Analysis

Project Value/Returns

Equity and Debt Invested 

Net Cash After Operations

Net (Outflow)/Inflow

Weighted average cost of capitalInternal Rate of ReturnNet Present ValueEquity Value/Returns

Equity Invested 

Dividends Paid 

Terminal Value

Net (Outflow/Inflow) 

Cost of EquityInternal Rate of ReturnNet Present Value

Eastman Kodak

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4) (b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Working Capital Analysis

Increase/(Decrease) in ReceivablesIncrease/(Decrease) in Inventory(Increase)/Decrease in Payables

Net Working Capital Cost

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Pr

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

9/2/2020 4:08 PM Eastman Kodak Financial Pr

(b) (4)
Balance Sheet

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Assets

Current AssetsCashDebt Service Reserve/Restricted Cash Accounts ReceivableInventory

Total Current Assets

Non-Current AssetsConstruction of SAPIR WarehouseIT Systems for SAPIR Warehouse

Construction of Hybrid Manufacturing FacilityEquipment for Hybrid Manufacturing FacilityIT Systems for Hybrid Manufacturing FacilityRenovation of facility for Center of ExcellenceEquipment for Center of ExcellenceIT Systems for Center of ExcellenceRenovation for reagent manufacturing facilitiesEquipment for reagent manufacturing facilitiesIT Systems for reagent manufacturing facilitiesAssets ContributedOngoing Cap Ex Procurement Essential Medicines for Shortage - Accumulated Depreciation

Total Non-Current Assets

Total Assets

Liabilities and Net Worth

Current Liabilities

Accounts Payable

Short Term Debt 

Current Portion -- Long Term Debt

Total Current Liabilities

Non-Current Liabilities

Long Term Debt-Senior

Eastman Kodak

9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)
Subordinated Debt

Total Non-Current Liabilities

Net Worth/Stockholders Equity

Stock and Paid in Capital

Retained Earnings

Total Net Worth

Total Liabilites and Net Worth

Reconciliation

9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)
Balance Sheet

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)
9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)

(b) (4)
Sources and Uses

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Uses of FundsConstruction of SAPIR Warehouse IT Systems for SAPIR Warehouse Construction of Hybrid Manufacturing Facility Equipment for Hybrid Manufacturing Facility IT Systems for Hybrid Manufacturing Facility Renovation of facility for Center of Excellence Equipment for Center of Excellence IT Systems for Center of Excellence Renovation for reagent manufacturing facilities Equipment for reagent manufacturing facilities IT Systems for reagent manufacturing facilities Assets Contributed Ongoing Cap Ex

Procurement Essential Medicines for Shortage - Not De 

Project-Related Working Capital Funding of Debt Service Reserve Interest/Fees During ConstructionContingency

Annual Total

Total Project Cost

Sources of FundsDFC Debt Disbursements 

Other LT and Subordinated Debt Disb New Equity Contributions 

Annual Total 

Total Financing

Eastman Kodak

9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)
Sources and Uses

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 4:08 PM Eastman Kodak Financial Projectio

(b) (4)
Ratio Analysis

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Liquidity Ratios

Quick Ratio

Current Ratio

Leverage Ratios

Debt/Equity

Senior Debt/Sub-debt+Equity

Cash Flow and Debt Service Coverage Statistics

Operating Cash Flow (USD)

Operating CADS/Interest+Fees

Operating CADS/Scheduled Principal

Operating CADS/Total Debt Service

Profitability Statistics

EBITDA (USD)

EBITDA (%)

Net Income (USD)

Net Income (%)

Return Statistics

Project IRR

Project NPV

Equity IRR

Equity NPV

Eastman Kodak

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4) (b) (4)
Ratio Analysis

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 4:08 PM Eastman Kodak Financial Projection

(b) (4)
TEMPLATE LAST REVISED ON: 1/1/2020

Enter Project/Company Name

 

 

7/1/2020

Eastman Kodak

Enter Target Date for 

First Disbursement of 

DFC-Supported Debt
Project Assumptions

Calendar Year 2020 

Eastman Ko

Revenues in $000s

High Volume APIsNumber of Units sold annually KilogramsPrice per Unit (local currency)Currency conversion (local currency per USD)High Volume APIs Revenue in $000sSPIR Warehousing RevenueNumber of Units sold annually Square FeetPrice per Unit (local currency)Currency conversion (local currency per USD)SPIR Warehousing Revenue Revenue in $000sReagentsNumber of Units sold annually LitersPrice per Unit (local currency)Currency conversion (local currency per USD)Reagents Revenue in $000sNon-Regulated KSMsNumber of Units sold annually KilogramsPrice per Unit (local currency)Currency conversion (local currency per USD)Non-Regulated KSMs Revenue in $000sLow Volume APIsNumber of Units sold annually KilogramsPrice per Unit (local currency)Currency conversion (local currency per USD)Low Volume APIs Revenue in $000sCost of Goods Sold as % of Total Sales Revenue

Cost of Goods Sold in $000sIndirect/Overhead Costs

Local Currency Costs

Operating Costs in $000s

Total Sales Revenues in $000s

9/2/2020 3:22 PM Page 2 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

Calendar Year 2020 Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Operating Expense (local 000s) Total Local Currency Cost (local 000s) 

Conversion (local currency per USD)

Total Local currency cost in $000s 

US Dollar Costs

Startup, Accreditation and other one-time ItemsResearch and DevelopmentDirect SG&ACorporate FunctionsResearch Labs Facility Costs (net of lease income) 

Total US Dollar Costs ($000s)

Total Indirect Costs ($000s)

9/2/2020 3:22 PM Page 3 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

Calendar Year 2020 

Capital Costs in $000s

Capital Expenditures (Up-front costs)

Construction of SAPIR Warehouse

IT Systems for SAPIR Warehouse

Construction of Hybrid Manufacturing Facility

Equipment for Hybrid Manufacturing Facility

IT Systems for Hybrid Manufacturing Facility

Renovation of facility for Center of Excellence

Equipment for Center of Excellence

IT Systems for Center of Excellence

Renovation for reagent manufacturing facilities

Equipment for reagent manufacturing facilities

IT Systems for reagent manufacturing facilities

Assets Contributed

Ongoing Cap Ex

Procurement Essential Medicines for Shortage - Not Depreciated

DFC Debt Assumptions and Schedule

Total Loan Amount in $000s 765,000 Base Interest Cost (%)Interest Risk Spread (%) 0.00%

All-in Annual Interest Rate (%)

Commitment Fee (%) 0.00% Facility/Administrative Fee (%) 0.00%Total Loan Term (months) 300Grace Period on Principal Repayment (months)# of payments per yearEstimated Date of First Drawdown 07/01/20

Estimated Date of First Principal Repayment 01/01/24Estimated Maturity Date 07/01/45Number of Principal PaymentsStraight-line or Mortgage-Style?# of principal Payments if quarterly 0# of principal Payments if semi-annual 0

0

Outstanding Principal (Start of Year)DFC Debt Principal Disbursements in $000sDFC Debt Fees (Facility, Commitment) DFC Debt InterestDFC Debt Principal Repayments 

Total Annual Capital Expenditures

BmDFDb

9/2/2020 3:22 PM Page 4 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
Project Assumptions

Calendar Year 2020 

Total DFC Debt Service 9,000 

Outstanding Principal (End of Year) 360,000 

Other Senior Debt -- Assumptions and Schedule

Name of LenderAnnual Interest Rate (%) 0%Outstanding Principal (Start of Year) 0Principal Disbursements (in $000s) 0Fees (in $000s) 0Interest 0Principal Repayments (in $000s) 0

Total Other Senior Debt Service 0

Outstanding Principal (End of Year) 0

Name

Note: Multiple senior debt sources are noconsult your DFC contact before making debt sources.

9/2/2020 3:22 PM Page 5 Eastman Kodak Financial Projections_2019 
Project Assumptions

Calendar Year 2020 

Short Term Debt -- Assumptions and Schedule

Name of LenderAnnual Interest Rate (%) 0%Outstanding Principal (Start of Year) 0Principal Disbursements (in $000s) 0Fees (in $000s) 0Interest 0Principal Repayments (in $000) 0

Total Short Term Debt Service 0

Outstanding Principal (End of Year) 0

Subordinated Debt -- Assumptions and Schedule

Name of LenderOutstanding Principal (Start of Year) 0Principal Disbursements ($000s) 0Fees or Interest (if allowed) ($000s) 0Principal Repayments ($000s) 0

Total Subordinated Debt Service 0

Outstanding Principal (End of Year) 0

Equity and Reconciliation of Retained Earnings

Equity (Start of Year) in $000sNew Equity Contributions in $000sEquity (End of Year)Retained Earnings (Start of Year)Net IncomeDividend Payout Ratio (%)Dividends Paid Retained Earnings (End of Year)

Income Tax Assumptions

Tax Rate 0% 

Depreciation/Amortization Assumptions

Year Depreciation/Amortization Begins

NameName

Note: Other debt sources are not approconsult your DFC contact before making debt facilities.

Note: Some projects may structure equity as subordina

somewhat unusual for an DFC-supported project, so ple

regarding subordinated debt.

9/2/2020 3:22 PM Page 6 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

Calendar Year

Construction of SAPIR Warehouse

IT Systems for SAPIR Warehouse

Construction of Hybrid Manufacturing Facility

Equipment for Hybrid Manufacturing Facility

IT Systems for Hybrid Manufacturing Facility

Renovation of facility for Center of Excellence

Equipment for Center of Excellence

IT Systems for Center of Excellence

Renovation for reagent manufacturing facilities

Equipment for reagent manufacturing facilities

IT Systems for reagent manufacturing facilities

Assets Contributed

Ongoing Cap Ex

Total Annual Depreciation Exp.

9/2/2020 3:22 PM Page 7 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

Calendar Year 2020 

Working Capital and Debt Service Reserve Assumptions

Days in ReceivablesDays InventoryDays in PayablesMonths Debt Service to Restricted Cash 

Cost of Capital (for Net Present Value Calculation Purposes)

Amount of DFC DebtAmount of other Senior DebtAmount of Sub-Debt/Equity

Total Project Capitalization

Cost of DebtCost of EquityWeighted Average Cost of Capital

9/2/2020 3:22 PM Page 8 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

9/2/2020 3:22 PM Page 9 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

9/2/2020 3:22 PM Page 10 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

Anchor Date

"

ry rate for comparable 

 ate. Discuss w/ your 

e, enter "2"

 Discuss with your DFC contact 

terly

9/2/2020 3:22 PM Page 11 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

000000000000000000000000000000000000000000000000000000000000000

9/2/2020 3:22 PM Page 12 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000

0% 0% 0% 0% 0% 0% 0% 0% 0%

m a 3rd party. This is 

g any assumptions 

9/2/2020 3:22 PM Page 13 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

9/2/2020 3:22 PM Page 14 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2024 2025 2026 2027 2028 2029 2030 2031 2032 20

9/2/2020 3:22 PM Page 15 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 16 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 17 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 18 Eastman Kodak Financial Projections_2019 

(b) (4) (b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 19 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 20 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 21 Eastman Kodak Financial Projections_2019 

(b) (4)
Project Assumptions

2036 2037 2038 2039 2040 2041 2042 2043 2044 204

9/2/2020 3:22 PM Page 22 Eastman Kodak Financial Projections_2019 

(b) (4)
Income Statement

Calendar Year 2020 2021 2022 2023 2024 2025 

Projected Projected Projected Projected Projected Project

RevenuesHigh Volume APIs Revenue in $000sSPIR Warehousing Revenue Revenue in $000sReagents Revenue in $000sNon-Regulated KSMs Revenue in $000sLow Volume APIs Revenue in $000s

Gross Revenues

Cost of Product SoldOperating Expenses

Operating Expense (local 000s)Operating Expense (local 000s)Operating Expense (local 000s)Operating Expense (local 000s)Operating Expense (local 000s)

Startup, Accreditation and other one-time Items

Research and Development

Direct SG&A

Corporate Functions

Research Labs Facility Costs (net of lease income)

Total Operating Expenses

Gross Operating Profit (EBITDA)Depreciation Expense

EBIT

Interest & Fee Income/(Expense)Income TaxesNet IncomeDividendsAddition to Retained Earnings

Eastman 

9/2/2020 3:22 PM Eastman Kodak Financial Projections_20

(b) (4)
Income Statement

2028 2029 2030 2031 2032 2033 2034 2035 2036 203

Projected Projected Projected Projected Projected Projected Projected Projected Projected Project

9/2/2020 3:22 PM Eastman Kodak Financial Projections_20

(b) (4)
Income Statement

2040 2041 2042 2043 2044 2045

Projected Projected Projected Projected Projected Projected

9/2/2020 3:22 PM Eastman Kodak Financial Projections_20

(b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Projected Projected Projected Projected Projected Projected Projected Projected Projected 

Cash Flow Statement

SalesChange in Receivables

Cash from Sales

Cost of Goods SoldChange in InventoryChange in Payables/Other Curr. Liabilities

Cash Production Costs

Gross Cash Profits

Cash Operating Expenses

Cash After Operations

Taxes Paid

Net Cash After Operations

Capital Expenditures

Net Cash After Investing Activities

Interest & Fee Income/(Expense)

Dividends PaidShort Term Debt Inflow/(Outflow)LT Senior Debt Inflow/(Outflow)Subordinated Debt Inflow/(Outflow)Equity Inflow/(Outflow)

Net Cash After Financing Activities

Beginning Cash

Change in Cash

Cash (to)/from debt reserve

Ending Cash

Eastman Kodak

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Debt Service Coverages/Cash Available for Debt Service (CADS)

Operating Debt Service CoverageNet Cash After Operations(Operating CADS)Net Interest & Fee ExpensePrincipal Payments

Total Debt Service

Operating CADS/Interest & FeeOperating CADS/PrincipalOperating CADS/Total Debt ServiceAverage Debt Service CoverageTotal Debt Service CoverageNet Cash Flow+Interest & Fee Expense+Principal Repayment+Dividends Paid 

Total CADS

Interest & Fee ExpensePrincipal Repayment

Total Debt Service

Total CADS/Interest+FeeTotal CADS/Scheduled PrincipalTotal CADS/Total Debt ServiceAverage Debt Service Coverage

Discounted Cash Flow (DCF)/Net Present Value (NPV) Analysis

Project Value/Returns

Equity and Debt Invested 

Net Cash After Operations

Net (Outflow)/Inflow

Weighted average cost of capitalInternal Rate of ReturnNet Present ValueEquity Value/Returns

Equity Invested 

Dividends Paid 

Terminal Value

Net (Outflow/Inflow) 

Cost of EquityInternal Rate of ReturnNet Present Value

Eastman Kodak

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4) (b) (4)
Cash Flow Statement

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 2028 

Working Capital Analysis

Increase/(Decrease) in ReceivablesIncrease/(Decrease) in Inventory(Increase)/Decrease in Payables

Net Working Capital Cost

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Pr

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4)
Cash Flow Statement

2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

9/2/2020 3:22 PM Eastman Kodak Financial Projections

(b) (4)
Balance Sheet

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Assets

Current AssetsCashDebt Service Reserve/Restricted CashAccounts ReceivableInventory

Total Current Assets

Non-Current AssetsConstruction of SAPIR WarehouseIT Systems for SAPIR WarehouseConstruction of Hybrid Manufacturing FacilityEquipment for Hybrid Manufacturing FacilityIT Systems for Hybrid Manufacturing FacilityRenovation of facility for Center of ExcellenceEquipment for Center of ExcellenceIT Systems for Center of ExcellenceRenovation for reagent manufacturing facilitiesEquipment for reagent manufacturing facilitiesIT Systems for reagent manufacturing facilitiesAssets ContributedOngoing Cap ExProcurement Essential Medicines for Shortage - N

Accumulated Depreciation

Total Non-Current Assets

Total Assets

Liabilities and Net Worth

Current Liabilities

Accounts Payable

Short Term Debt

Current Portion -- Long Term Debt

Total Current Liabilities

Non-Current Liabilities

Long Term Debt-Senior

Eastman Kodak

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
Subordinated Debt

Total Non-Current Liabilities

Net Worth/Stockholders Equity

Stock and Paid in Capital

Retained Earnings

Total Net Worth

Total Liabilites and Net Worth

Reconciliation

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
Balance Sheet

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
Sources and Uses

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Uses of FundsConstruction of SAPIR WarehouseIT Systems for SAPIR WarehouseConstruction of Hybrid Manufacturing FacilityEquipment for Hybrid Manufacturing FacilityIT Systems for Hybrid Manufacturing FacilityRenovation of facility for Center of ExcellenceEquipment for Center of ExcellenceIT Systems for Center of ExcellenceRenovation for reagent manufacturing facilitiesEquipment for reagent manufacturing facilitiesIT Systems for reagent manufacturing facilitiesAssets ContributedOngoing Cap ExProcurement Essential Medicines for Shortage - Not De

Project-Related Working CapitalFunding of Debt Service ReserveInterest/Fees During ConstructionContingency

Annual Total

Total Project Cost

Sources of FundsDFC Debt DisbursementsOther LT and Subordinated Debt DisbNew Equity Contributions

Annual Total

Total Financing

Eastman Kodak

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
Sources and Uses

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 

(b) (4)
Ratio Analysis

Calendar Year 2020 2021 2022 2023 2024 2025 2026 2027 

Projected Projected Projected Projected Projected Projected Projected Projected 

Liquidity Ratios

Quick Ratio

Current Ratio

Leverage Ratios

Debt/Equity

Senior Debt/Sub-debt+Equity

Cash Flow and Debt Service Coverage Statistics

Operating Cash Flow (USD)

Operating CADS/Interest+Fees

Operating CADS/Scheduled Principal

Operating CADS/Total Debt Service

Profitability Statistics

EBITDA (USD)

EBITDA (%)

Net Income (USD)

Net Income (%)

Return Statistics

Project IRR

Project NPV

Equity IRR

Equity NPV

Eastman Kodak

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 0

(b) (4) (b) (4)
Ratio Analysis

2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 

Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected Projected 

9/2/2020 3:22 PM Eastman Kodak Financial Projections_2019 0

(b) (4)
Building Abstract for: 028-KP

Bulding Code 028-KP

Building Name Building 28

Address 1: 200 Ridge Road West

Address 2: Rochester, N.Y.

Site Code: KP-BSSD

Sector Code KPE

Maintenance zone SOUTHEAST

Bldg. Contact Tom Shaughnessy

Ciontact Phone:

Building Use OFFICE

Year Built 1948

Hazard Rating LOW

Building Condition GOOD

Date Rehab:

Ext. Gross Area:

Int. Gross Area:

Ext. Wall Area:

Frame Type: CONC/STL

Column Spacing: 20' North & South

Ceiling Type: ceiling tiles in offices

pan ceilings in some corridors

Celing Height: Offices 9' ceilings, 12' to slab

Exterior Walls: Brick

Floor Structure: concrete reinforced slab

Floor Loading Cap.: 110#/s

Floor Covering: Terrazzo floors in main lobby, 1st

floor corridor and cafeteria

Roof Structure: Concrete deck

Roof Covering: Built-up asphalt

Class A roof

Interior Components: Hauserman, studs, dry wall, block

Banking:

Foundation Type: CONC/STL Shower Rooms: Men's&Women's 4th flr&fitness cntr, 

dressing rms 2nd & 3rd flrs

Locker Rooms: Men's&Women's 4th flr&fitness cntr

Restrooms: Men's&Women's each flr;SB-4th

Electrical/Lighting Major portion (90%) of the building light 

fixtures have been retrofitted

Elevators Passenger 232 & 233

Kitchen freight 234 & 235

Building freight 236

HVAC: Seven air handling systems

Six exhaust systems

BAS controlled except for AS 5 Theater

Sprinklers: Large assembly areas and rooms are not 

sprinklered

Utilities: Chilled Water, Kodak Water, 70# Steam, 

Low Pressure Steam, (1) 480V Load Cntr 

& (1) 208/120V Load Cntr

Grade Level Access: Main lobby, Ridge Road entrance, 

Doors D and Door P

Docks Dock M-main dock 

Dock F-Construction material dock

Rail Access N\A

Industrial Sewer: YES

Sanitary Sewer YES

Floor Info.:

Floor Name Int. Gross Area Ext. Gross Area

Basement

First Floor

Second Floor

Third Floor

Fourth Floor

Fifth Floor

Sixth Floor

Seventh Floor

Sub-basement

Number of Floors:

Total Gross Area:

Saturday, May 06, 2017 Page 1 of 2

(b) (4)

(b) (4)

(b) (6)
BreakRooms: NA

Cafeterias: Flr 1 Dining Rm; Flr 2 full svc cafete

Special Features: B28 is a perimeter building

B28 public use by invitation

B28 maintains recreational facilities, 

theater/conferencing facilities

Building Occupancy (Top 5)

BSSD-BUILDINGS 280351.14

RSVD-NO 39893.41

EKC-HSE 13673.96

IMPACT V-BALL 13135.93

MONROE COMM 11700.55

Saturday, May 06, 2017 Page 2 of 2
(b) (4)
(b) (4)